

1           **SARS-CoV-2 ferritin nanoparticle vaccines elicit broad SARS coronavirus immunogenicity**  
2  
3

4 M. Gordon Joyce<sup>1,2,12,\*</sup>, Wei-Hung Chen<sup>1,2</sup>, Rajeshwer S. Sankhala<sup>1,2</sup>, Agnes Hajduczki<sup>1,2</sup>, Paul V.  
5 Thomas<sup>1,2</sup>, Misook Choe<sup>1,2</sup>, William Chang<sup>1,2</sup>, Caroline E. Peterson<sup>1,2</sup>, Elizabeth Martinez<sup>1,2</sup>, Elaine B.  
6 Morrison<sup>4</sup>, Clayton Smith<sup>5,6</sup>, Aslaa Ahmed<sup>7</sup>, Lindsay Wieczorek<sup>2,4</sup>, Alexander Anderson<sup>2,4</sup>, Rita E. Chen<sup>3</sup>,  
7 James Brett Case<sup>3</sup>, Yifan Li<sup>2,4</sup>, Therese Oertel<sup>2,4</sup>, Lorean Rosado<sup>2,4</sup>, Akshaya Ganesh<sup>2,4</sup>, Connor Whalen<sup>2,4</sup>,  
8 Joshua M. Carmen<sup>4</sup>, Letzibeth Mendez-Rivera<sup>2,4</sup>, Christopher Karch<sup>2,4</sup>, Neelakshi Gohain<sup>2,4</sup>, Zuzana  
9 Villar<sup>2,4</sup>, David McCurdy<sup>2,4</sup>, Zoltan Beck<sup>2,4</sup>, Jiae Kim<sup>2,4</sup>, Shikha Shrivastava<sup>2,4</sup>, Ousman Jobe<sup>2,4</sup>, Vincent  
10 Dussupt<sup>2,4</sup>, Sebastian Molnar<sup>2,4</sup>, Ursula Tran<sup>2,4</sup>, Chandrika B. Kannadka<sup>2,4</sup>, Michelle Zemil<sup>2,4</sup>, Htet Khanh<sup>5,6</sup>,  
11 Weimin Wu<sup>5,6</sup>, Matthew A. Cole<sup>8</sup>, Debra K. Duso<sup>8</sup>, Larry W. Kummer<sup>8</sup>, Tricia J. Lang<sup>8</sup>, Shania E. Muncil<sup>8</sup>,  
12 Jeffrey R. Currier<sup>7</sup>, Shelly J. Krebs<sup>2,4</sup>, Victoria R. Polonis<sup>4</sup>, Saravanan Rajan<sup>9</sup>, Patrick M. McTamney<sup>10</sup>,  
13 Mark T. Esser<sup>10</sup>, William W. Reiley<sup>8</sup>, Morgane Rolland<sup>2,4</sup>, Natalia de Val<sup>5,6</sup>, Michael S. Diamond<sup>3</sup>, Gregory  
14 D. Gromowski<sup>7</sup>, Gary R. Matyas<sup>4</sup>, Mangala Rao<sup>4</sup>, Nelson L. Michael<sup>11</sup>, and Kayvon Modjarrad<sup>1,\*</sup>

- 15  
16 1. Emerging Infectious Diseases Branch, Walter Reed Army Institute of Research, Silver Spring, MD,  
17 USA.  
18 2. Henry M. Jackson Foundation for the Advancement of Military Medicine, Bethesda, MD, USA.  
19 3. Department of Medicine, Washington University School of Medicine, St. Louis, MO 63110, USA;  
20 Department of Pathology & Immunology, Washington University School of Medicine, St. Louis, MO  
21 63110, USA; Department of Molecular Microbiology, Washington University School of Medicine,  
22 St. Louis, MO 63110, USA; The Andrew M. and Jane M. Bursky Center for Human Immunology &  
23 Immunotherapy Programs, Washington University School of Medicine, St. Louis, MO 63110, USA.  
24 4. U.S. Military HIV Research Program, Walter Reed Army Institute of Research, Silver Spring, MD,  
25 USA.  
26 5. Center for Molecular Microscopy, Center for Cancer Research, National Cancer Institute, National  
27 Institutes of Health, Frederick, MD, USA.  
28 6. Cancer Research Technology Program, Frederick National Laboratory for Cancer Research, Leidos  
29 Biomedical Research Inc., Frederick, MD, USA.  
30 7. Viral Diseases Branch, Walter Reed Army Institute of Research, Silver Spring, MD, USA.  
31 8. Trudeau Institute, Inc., Saranac Lake, NY, USA.  
32 9. Antibody Discovery and Protein Engineering (ADPE), BioPharmaceuticals R&D, AstraZeneca,  
33 Gaithersburg, USA  
34 10. Microbial Sciences, BioPharmaceuticals R&D, AstraZeneca, Gaithersburg, MD, USA.  
35 11. Center for Infectious Diseases Research, Walter Reed Army Institute of Research, Silver Spring, MD,  
36 USA.  
37 12. Lead contact

38  
39 \*Correspondence: [gjoyce@eidresearch.org](mailto:gjoyce@eidresearch.org) (MGJ), [kayvon.modjarrad.civ@mail.mil](mailto:kayvon.modjarrad.civ@mail.mil) (KM)

40 **SUMMARY**

41  
42 The need for SARS-CoV-2 next-generation vaccines has been highlighted by the rise of variants of concern  
43 (VoC) and the long-term threat of other coronaviruses. Here, we designed and characterized four categories  
44 of engineered nanoparticle immunogens that recapitulate the structural and antigenic properties of prefusion  
45 Spike (S), S1 and RBD. These immunogens induced robust S-binding, ACE2-inhibition, and authentic and  
46 pseudovirus neutralizing antibodies against SARS-CoV-2 in mice. A Spike-ferritin nanoparticle (SpFN)  
47 vaccine elicited neutralizing titers more than 20-fold higher than convalescent donor serum, following a  
48 single immunization, while RBD-Ferritin nanoparticle (RFN) immunogens elicited similar responses after  
49 two immunizations. Passive transfer of IgG purified from SpFN- or RFN-immunized mice protected K18-  
50 hACE2 transgenic mice from a lethal SARS-CoV-2 virus challenge. Furthermore, SpFN- and RFN-  
51 immunization elicited ACE2 blocking activity and neutralizing ID50 antibody titers >2,000 against SARS-  
52 CoV-1, along with high magnitude neutralizing titers against major VoC. These results provide design  
53 strategies for pan-coronavirus vaccine development.  
54  
55

56 **Keywords:** SARS-CoV-2, ferritin nanoparticle, Spike, receptor binding domain, COVID-19,  
57 SARS-CoV-1,  $\beta$ -coronaviruses, variants of concern, B.1.1.7, B.1.351, P.1, ALFQ, neutralizing  
58 antibodies  
59

60  
61 **HIGHLIGHTS**

- 62  
63 - Iterative structure-based design of four Spike-domain Ferritin nanoparticle classes of  
64 immunogens  
65 - SpFN-ALFQ and RFN-ALFQ immunization elicits potent neutralizing activity against  
66 SARS-CoV-2, variants of concern, and SARS-CoV-1  
67 - Passively transferred IgG from immunized C57BL/6 mice protects K18-hACE2 mice  
68 from lethal SARS-CoV-2 challenge  
69  
70

## 71 INTRODUCTION

72  
73 Seven coronaviruses (CoV) cause disease in humans, with three of these, SARS-CoV-1, MERS-  
74 CoV, and SARS-CoV-2 having emerged since 2003 (Cui et al., 2019) and displaying high  
75 mortality rates. SARS-CoV-2 is easily transmitted by humans and created a pandemic,  
76 infecting over 100 million people, causing over 2 million deaths to date, and resulting in an  
77 urgent need for protective and durable vaccines. Rapid vaccine development in a worldwide  
78 effort, led to the evaluation of hundreds of SARS-CoV-2 vaccine candidates and rapid  
79 worldwide vaccine distribution and use.

80 The response to SARS-CoV-2 was facilitated by multiple efforts over the last decade  
81 to enable CoV pandemic preparedness, initially based on MERS-CoV vaccine design and  
82 development (Wang et al., 2015), phase I vaccine trials (Modjarrad et al., 2019), and a global  
83 effort by the Coalition for Epidemic Preparedness Innovations (CEPI) to advance vaccine  
84 candidates (Plotkin, 2017). The elucidation of CoV Spike (S) glycoprotein structures  
85 (Kirchdoerfer et al., 2016; Walls et al., 2016) allowed structure-based vaccine design of  
86 stabilized S glycoprotein immunogens from multiple CoVs (Pallesen et al., 2017), providing  
87 a blueprint for SARS-CoV-2 vaccine design (Corbett et al., 2020).

88 The CoV S protein mediates virus entry, is immunogenic (Iyer et al., 2020; Wang et al.,  
89 2021) and encodes multiple neutralizing epitopes (Greaney et al., 2021) making it the  
90 primary target for natural and vaccine-induced CoV humoral immunity and vaccine design  
91 (Jiang et al., 2020) and the target of most COVID-19 vaccines. S is a class I fusion glycoprotein  
92 consisting of a S1 attachment subunit and S2 fusion subunit that remain non-covalently  
93 associated in a metastable, heterotrimeric S on the virion surface (Walls et al., 2020). In the  
94 S1 subunit, there is a N-terminal domain (NTD), and C-terminal domain (CTD) that includes  
95 the receptor-binding domain (RBD). The RBD binds to the human angiotensin converting  
96 enzyme 2 (hACE2) facilitating cell entry (Lan et al., 2020). Multiple antigenic sites have been  
97 identified on the S protein, including distinct sites on the RBD and the S1 domain, including  
98 an NTD supersite (Brouwer et al., 2020; Cerutti et al., 2021; Liu et al., 2020; Zost et al., 2020).  
99 Convalescent serum antibodies or monoclonal antibodies capable of potently inhibiting  
100 infection *in vitro* can reduce disease severity or mortality in rodents, non-human primates  
101 (Barnes et al., 2020) and humans (Duan et al., 2020; Salazar et al., 2020; Shen et al., 2020).

102 Due to the unknown parameters of SARS-CoV-2 vaccine durability, specific age- or  
103 population-needs, emergence of SARS-CoV-2 variants of concern (VoC) (Wibmer et al.,  
104 2020), and the constant threat of emerging CoV pathogens (Menachery et al., 2015), second-  
105 generation COVID-19 or pan-sarbecovirus vaccines will be needed. Iterative structure-based  
106 design for viral glycoproteins (McLellan et al., 2013; Joyce et al., 2016) stabilizing  
107 neutralizing epitopes or epitope-based vaccine design (Chen et al., 2021; Kong et al., 2019)  
108 show that rational vaccine design can lead to the elicitation of broad immune responses.  
109 Broad cross-reactive responses elicited by engineered vaccines have also been advanced for  
110 influenza (Boyoglu-Barnum et al., 2020; Kanekiyo et al., 2019). In the case of CoVs, a set of  
111 cross-reactive epitopes have recently been described (Barnes et al., 2020; Joyce et al., 2020;  
112 Sauer et al., 2021; Wrapp et al., 2020), with many of the preferred neutralizing antibodies  
113 centered on the RBD domain (Li et al., 2021; Pinto et al., 2020; Rappazzo et al., 2021).

114 Next-generation strategies to augment specific immune responses as well as enhance  
115 cross-reactivity include the use of nanoparticle vaccine technology (Cohen et al., 2021) and  
116 next-generation adjuvants. Nanoparticle technologies have been shown to improve antigen

117 structure and stability, as well as vaccine targeted delivery, immunogenicity, with good  
118 safety profiles (Pati et al., 2018). Engineered nanoparticle-vaccines can elicit broader  
119 immune responses (Darricarrere et al., 2021; Kanekiyo et al., 2019; Kanekiyo et al., 2013)  
120 or more efficacious immune responses (Kanekiyo et al., 2015). The repetitive array of the  
121 viral surface component allows for robust B-cell activation facilitating memory B cell  
122 expansion and generation of long-lived plasma cells. More recently, in efforts to generate  
123 more effective vaccines that can prevent infection by resistant pathogens such as HIV-1 or  
124 Influenza, a set of engineered nanoparticle vaccines have been developed. Utilizing naturally  
125 occurring nanoparticle molecules such as bacterial ferritin, antigens are fused to the ferritin  
126 molecule to recapitulate complex trimeric class I glycoproteins, and to increase the immune  
127 response for weakly immunogenic targets. Nanoparticle technologies have also been shown  
128 to improve antigen structure and stability, as well as vaccine targeted delivery,  
129 immunogenicity and safety (Pati et al., 2018). Recently designed single and multi-component  
130 nanoparticle vaccines (Brouwer et al., 2021; Walls et al., 2020) show promise from both an  
131 immunological (Cawfield et al., 2019; Marcandalli et al., 2019) and a cGMP production  
132 perspective (Ueda et al., 2020).

133 Engineered nanoparticle vaccines and their capacity to generate enhanced immune  
134 responses in humans are currently being studied and include influenza (NCT03186781;  
135 NCT03814720; NCT04579250), Epstein-Barr virus (NCT04645147), malaria  
136 (NCT04296279) and a recently described SARS-CoV-2 nanoparticle vaccine (IVX-411)  
137 (Walls et al., 2020). Use of potent adjuvants such as liposomal-saponin adjuvants can further  
138 enhance the protective immune response (Cawfield et al., 2019; Lal et al., 2015; Om et al.,  
139 2020) even in the context of nanoparticle vaccines (Langowski et al., 2020) (Kaba et al.,  
140 2018). Based on the results described herein and data from associated non-human primate  
141 experiments (Joyce et al., 2021; King et al., 2021), a S-Ferritin immunogen with a liposomal  
142 adjuvant, ALFQ is currently being assessed in a phase I clinical trial (NCT04784767).

143 Here we report the structure-based design and pre-clinical assessment of four  
144 categories of S-domain ferritin nanoparticles including stabilized S-trimer-ferritin  
145 nanoparticles (SpFN), RBD-ferritin nanoparticles (RFN), S1-ferritin nanoparticles, and RBD-  
146 NTD-ferritin nanoparticles. By using a set of biophysical, structural, and antigenic  
147 assessments, combined with animal immunogenicity testing, we identify multiple  
148 immunogens that elicit substantial neutralizing antibody titers against SARS-CoV-2 and  
149 related VoC. These antibody levels provide robust protection against SARS-CoV-2 challenge  
150 in the K18-hACE2 mouse model. We further show that subsequent immunizations not only  
151 increase the SARS-CoV-2 neutralization titer, but also expand the neutralization breadth and  
152 titer against the heterologous SARS-CoV-1 virus. These data provide multiple immunogen  
153 design strategies for pan-betacoronavirus vaccine development.

## 154 155 **RESULTS**

### 156 157 **Immunogen Design of SARS-CoV-2 S-domain Ferritin Nanoparticles**

158  
159 Using the initial SARS-CoV-2 genome sequence (Genbank: MN9089473), we designed four  
160 categories of S-domain ferritin-fusion recombinant proteins as immunogens for expression  
161 as nanoparticles based on the major antigenic domains of the S ectodomain (Figure S1). The  
162 *Helicobacter pylori* ferritin molecule was genetically linked to the C-terminal region of the

163 following S antigens (i) S ectodomain (residues 12-1158) (ii) RBD (residues 331-527), (iii)  
164 RBD linked in tandem to the NTD (residues 12-303), and (iv) S1 (residues 12-696) (Figure  
165 1, Figure S1, and Table S1). In the case of the Spike ferritin nanoparticle designs, a short  
166 linker to the ferritin molecule was used to utilize the natural three-fold axis, for display of  
167 eight Spikes. In the case of the other designs, a short region of bullfrog ferritin was utilized  
168 to allow equidistant distribution of the 24 S-domain molecules on the ferritin surface (Figure  
169 1). Our overall approach was to compare and contrast the immunogen structures,  
170 antigenicity, immunogenicity elicited by these different immunogens with the goal to  
171 identify the best immunogen to take forward into further development.

172 The first design category, Spike ferritin nanoparticle designs were based on a  
173 modified S with stabilizing prolines (K986P, V987P), removal of the furin cleavage site (RRAS  
174 to GSAS), and optimization of the coiled coil region between hinge 1 and hinge 2 of the  
175 ectodomain stalk (Turanova et al., 2020) to stabilize trimer formation on the Ferritin scaffold  
176 (Figure 1A and S1). The designs focused on (i) modification of the end of the S molecule  
177 (1137, 1208, 1154, or 1158), (ii) optimization of the coiled-coil region through extensions or  
178 repeats, (iii) removal of the coiled-coil region, (iv) removal of glycan 1158, (v) addition of  
179 heterogenous trimerization domains (GCN4, or foldon), or (vi) signal peptide sequence  
180 (Figure 1B, and Table S1).

181 The second design category, RBD ferritin nanoparticle designs used the SARS-CoV-2  
182 RBD (residues 331-527) (Figure 1C) connected to the bullfrog-H. pylori chimeric ferritin  
183 (Kanekiyo et al., 2015) by a 6 amino acid linker (Figure 1D). The SARS-CoV-2 RBD contains  
184 a set of hydrophobic patches, including the ACE2 binding site, and a region located about  
185 residue 518 that is covered in the context of the intact S molecule. These regions were  
186 iteratively mutated to reduce hydrophobicity, and increase stability of the RFN molecules,  
187 expression levels, and antigenicity and immunogenicity.

188 The third design category, RBD-NTD ferritin molecules were based on addition of  
189 optimized RBD molecules in series with an NTD-Ferritin construct (residues 12-303) linked  
190 to the bullfrog-H. pylori chimeric ferritin molecule. The in-series, but reversed RBD-NTD  
191 design ensured distal displacement of the RBD molecule from the ferritin molecule (Figure  
192 1E), promoting immune recognition of the RBD molecule with potential benefits for the  
193 production and stability of the nanoparticle.

194 The fourth design category, S1 ferritin design SARS-CoV-2 S (residues 12 - 676)  
195 (Figure 1F, and Table S1) was initially designed based on the MERS S1 immunogen which  
196 elicited protective immune responses (Wang et al., 2015). Subsequent designs focused on  
197 inclusion of a short region of SARS-CoV-2 S2 (residues 689-696) either using the connecting  
198 region that overlaps with the furin site, or by use of a short glycine-rich linker sequence  
199 (Figure 1F) to enable formation of the S1-Ferritin nanoparticle (Figure 1G).

200

## 201 **Characterization of SARS-CoV-2 S-domain ferritin nanoparticles**

202

203 Ten S-ferritin constructs (Table S1) were initially designed and tested for expression, yield,  
204 nanoparticle formation, and antigenicity. S-ferritin nanoparticles were expressed in  
205 Expi293F cells for 3-5 days at 34 °C and 37 °C and purified by GNA lectin affinity  
206 chromatography. A subset of these constructs showed reasonable expression levels ranging  
207 from 0.5 to 5 mg/L media supernatant (Figure S3). pCoV1B-05 and pCoV1B-06-PL (SpFN)  
208 typically yielded over 5 mg/L with expression incubation set at 34 °C. Samples were

209 assessed by SDS-PAGE, size-exclusion chromatography (SEC), dynamic light scattering  
210 (DLS), and negative-stain electron microscopy (neg-EM) to ensure intact protein was  
211 produced, and to assess the nanoparticle formation, and S morphology (Figure 2 and . For  
212 all SpFN constructs that showed expression as visualized by SDS-PAGE (Figure 2A),  
213 nanoparticles were observed by SEC, DLS, and neg-EM (Figure 2E, and 2F). In the case of  
214 SpFN and SpFN\_1B-08 (Figure S2), the globular shape of the protruding S was clearly  
215 visible in both the TEM images and the 2D averages. In the case of the pCoV1B-05, the  
216 protruding S showed more of an “open” form in both the TEM images and the 2D averages.

217 Nanoparticles were assessed for nanoparticle formation, and assessed for  
218 antigenicity using biolayer interferometry against a set of poorly neutralizing (CR3022,  
219 SR1), and potently neutralizing (SR2, SR3, SR4, SR5) RBD-targeting antibodies. The  
220 different S-ferritin designs showed variable binding to the antibodies, with SpFN having  
221 the highest binding (Figure 3A and Figure S1).

222 Initial test expression of RBD-Ferritin constructs at 37 °C using either 293F or  
223 Expi293F cells showed low levels of expression. Reducing the cell expression temperature  
224 to between 30 °C to 34 °C following transfection rescued expression and enabled levels >  
225 20 mg/L to be purified by NiNTA purification (Figure S3). However, analysis of the  
226 constructs by SEC, DLS, and neg-EM indicated that initial RBD-Ferritin constructs did not  
227 form fully intact nanoparticles (Figure S2). We hypothesized that designed variants with  
228 reduced RBD surface hydrophobicity would allow for improved nanoparticle yield.  
229 Screening through a set of variants using SDS-PAGE and SEC as primary indicators of  
230 nanoparticle formation allowed identification of constructs that readily formed  
231 nanoparticles (Figure 2 and Figure S1 and S2B). These molecules were also visualized by  
232 neg-EM, and showed clear formation of nanoparticles, with the protruding RBD domain  
233 visible on their surface in both TEM images and 2D class averages (Figure 2F). However,  
234 these constructs had a propensity to form soluble or insoluble aggregates and dramatically  
235 affected the ability to concentrate the samples. Addition of 5% glycerol to the NiNTA  
236 purified material, prior to SEC or other concentration steps, mitigated the aggregation issue  
237 and increased the nanoparticle formation as judged by SEC, and was confirmed by neg-EM.  
238 The RBD-Ferritin constructs showed very strong binding to the set of RBD-specific  
239 antibodies in all cases (Figure S3E). The level of binding was approximately twice that seen  
240 for the S-ferritin constructs, indicative of the exposed and accessible nature of the RBD  
241 epitopes (Figure 2G).

242 Due to the initial difficulty with S1-Ferritin nanoparticle constructs, we developed a  
243 set of engineered S1 constructs by artificially connecting the RBD domain by a short linker  
244 to NTD linked to the Ferritin molecule and denoted as RBD-NTD ferritin molecules. This  
245 multi-domain strategy resulted in good expression and nanoparticle formation. Using the  
246 information gained from the RBD surface optimization, we designed multiple constructs  
247 with variations in the RBD molecule to reduce surface hydrophobicity (Figure S1).  
248 Antigenic analysis of these constructs showed that pCoV146 displayed robust antibody-  
249 binding (Figure 2F).

250 The initial S1-Ferritin construct, pCoV68 (residues 12-676) yielded very low protein  
251 expression levels, even with reduced expression temperatures(Figure S3A). However,  
252 using the structure of the S-2P molecule (Wrapp et al., 2020; Walls et al., 2020), it was clear  
253 that a short segment of the S2 formed significant interactions with the S1 domain. Addition  
254 of this short region either using the natural sequence (with furin site removed) as in

255 construct pCoV109, or by linking residues 689-696 with glycine-rich linkers as in construct  
256 pCoV111 allowed ~ 1 mg/L of protein to be purified. Analysis of these constructs by SDS-  
257 PAGE, SEC, and neg-EM showed clear formation of the designed nanoparticles, and  
258 antigenic characterization showed binding of antibodies to the nanoparticle (Figure 2G).

259 Further structural analysis of the nanoparticle immunogens from each of the four  
260 design categories was carried out by determining 3D reconstructions from negative-stain  
261 electron micrographs (Figure 4). For each nanoparticle, a central sphere of approximately  
262 12 nm corresponding to ferritin was resolved. S-domain antigens were located a short  
263 distance away from the central sphere and linker regions were unresolved likely due to  
264 their small size and flexibility. The SpFN\_1B-06-PL reconstruction showed the stabilized S  
265 protruding from the ferritin molecule with a total diameter of approximately 44 nm (Figure  
266 4A). The large size and distinct low-resolution features of the S ectodomain allowed for  
267 docking of a closed S-2P trimer model (PDB ID: 6VXX) into the trimer density, confirming  
268 the S was in the prefusion conformation. The ferritin-distal region of the S density was  
269 slightly weaker and likely reflects the heterogeneity in RBD-up conformations or slight  
270 openings of trimer visible in raw micrographs. Additionally, although the coiled-coil was  
271 unresolved, the distances between the density for S and ferritin matched the modeled  
272 coiled-coil length. Reconstruction of the three-dimensional RFN\_131 EM map revealed two  
273 globular densities per asymmetric unit, suggesting that the RBD molecule was highly  
274 flexible on the surface of the ferritin sphere (Figure 4B). Similarly, the map of the RBD-  
275 NTD-ferritin fusion, pCoV146, showed two layers of globular densities, with a ferritin-  
276 proximal layer corresponding to the NTD domain and a more disordered layer for the RBD  
277 domain (Figure 4C). This particle was approximately 9nm larger in 2D and 3D than the  
278 single domain RFN molecule. The reconstruction of the S1-Ferritin fusion pCoV111  
279 revealed a surprisingly ordered S1 density compared to the flexible RBD-NTD fusion,  
280 perhaps due to geometric constraints on the surface of the ferritin particle (Figure 4D). A  
281 density similar in shape to the S1 domain in the closed S2P trimer was resolved although it  
282 was slightly more compact, likely due to both overall flexibility of the S1 on the ferritin  
283 surface and RBD flexibility.

## 284 285 **Immunogenicity of the four categories of SARS-CoV-2 S-domain ferritin nanoparticles** 286 **in mice**

287  
288 To evaluate the immunogenicity of the SARS-CoV-2 ferritin-nanoparticles, we typically  
289 utilized two strains of mice (C57BL/6, and BALB/c), two adjuvants (ALFQ, and Alhydrogel<sup>®</sup>),  
290 and immunized mice three-times intramuscularly at 3-week intervals using a 10 µg dose. In  
291 total, we assessed 14 immunogens, two Spike ferritin immunogens, seven RBD ferritin  
292 immunogens, one S1-Ferritin construct, and four RBD-NTD ferritin immunogens (Table S2).  
293 Assessment in immunogenicity studies was based on iterative knowledge of immunogen  
294 physical and biochemical characteristics (Figure 2 and 3, and Figure S3), in conjunction with  
295 immunogenicity results from first-generation immunogens (Figure S1). This facilitated  
296 down-selection of lead immunogen candidates. Alhydrogel<sup>®</sup> and ALFQ adjuvants were  
297 selected due to their history in human vaccine trials, safety profile, and previous  
298 performance alongside nanoparticle vaccine immunogens (NCT04296279). Alhydrogel<sup>®</sup>  
299 contains aluminum hydroxide gel, while ALFQ is a liposome-based adjuvant containing the

300 saponin QS-21, and synthetic Monophosphoryl Lipid A (3D-PHAD<sup>®</sup>). We assessed SARS-CoV-  
301 2 RBD- and S-binding, RBD-ACE2-inhibition, pseudovirus neutralizing antibody responses  
302 and authentic SARS-CoV-2 virus neutralization (Figure 4).

303 All four categories of immunogens elicited robust SARS-CoV-2 immune responses. In  
304 all cases tested, ALFQ was superior to Alhydrogel<sup>®</sup> as an adjuvant for elicitation of binding  
305 and neutralizing responses (Figure S4). In addition, Alhydrogel<sup>®</sup> led to a skewed antibody  
306 isotype immune response that was TH2 in nature, as opposed to the balanced immune  
307 response seen with ALFQ adjuvanted animals (Figure S4G). Immune responses seen in  
308 C57BL/6 mice were greater than for BALB/c mice after a single immunization, while binding  
309 and neutralizing antibody titers were comparable after a second or third immunization  
310 (Figure 5). In all cases, the third immunization did not dramatically increase the antibody  
311 levels induced by the S-domain ferritin nanoparticles.

312 The SpFN immunogen elicited a rapid RBD-binding, and pseudovirus neutralizing  
313 antibody response with ID<sub>50</sub> geometric mean titer (GMT) >10,000 in C57BL/6 mice and  
314 >1,000 after a single immunization (Figure 5C and Figure S4). This rapid neutralizing  
315 immune response after one immunization was significantly higher than seen with RBD  
316 ferritin or RBD-NTD ferritin immunogens. Following a second immunization, both strains of  
317 SpFN-vaccinated mice showed ID<sub>50</sub> GMT >10,000 and ID<sub>80</sub> GMT >5,000 for both mouse types.

318 RBD ferritin immunogens elicited robust RBD and S-binding responses, ACE2-  
319 inhibition, and pseudovirus neutralization ID<sub>50</sub> GMT >10,000 in both mice strains after two  
320 immunizations (Figure 5A-C). We assessed seven RFN immunogen designs in  
321 immunogenicity studies (Table S3) and selection for animal immunogenicity experiments  
322 was largely based on nanoparticle stability, expression levels, aggregation, and antigenic  
323 profile (Figure 2-3 and Figure S2, S3). Based on these criteria, pCoV131 (RFN) was  
324 extensively assessed, and after three immunizations, showed pseudovirus neutralization  
325 responses that were comparable or exceeded that seen for the SpFN\_1B-06-PL immunogen.  
326 Of note, the RFN immunogens elicited substantial S binding responses that were highly  
327 comparable to that of other immunogens that contained additional S domains (Figure 5B).

328 In a pattern similar to that seen for the RBD ferritin immunogens, both the RBD-NTD  
329 ferritin and the S1 ferritin immunogens elicited binding responses, and detectable  
330 pseudovirus neutralization after a single immunization that were increased by the second  
331 immunization to give ID<sub>50</sub> GMT values >10,000, and ID<sub>80</sub> GMT titers ~5,000 (Figure 5A-C and  
332 Figure S4).

333 Given the rapid elicitation of immune responses after a single immunization by  
334 SpFN\_1B-06-PL, we further characterized this immunogen in a dose-ranging study (Figure  
335 S5 and Figure 5D and 5E). In five-fold dilution steps, we reduced the SpFN\_1B-06-PL  
336 immunogen from a 10 µg dose down to a 0.0032 µg dose (3,125-fold reduction) with the full  
337 ALFQ adjuvant dose. Antibody binding responses were assessed for the full dose range by  
338 ELISA to S and RBD, and binding responses were elicited at all dose concentrations tested.  
339 We then further assessed the 0.08 µg dose (125-fold reduction from the 10 µg dose) with all  
340 our immunogenicity assays (Figure 5D and Figure S5G). At this dose, the immune response  
341 was comparable to that seen for the typical 10 µg dose. In addition, we assessed both the 10  
342 and 0.08 µg SpFN\_1B-06-PL vaccinated-mouse serum for authentic SARS-CoV-2 live virus  
343 neutralization. At both doses, in both mouse strains, a single immunization elicited ID<sub>50</sub> GMT  
344 of ~ 1,000, while the second immunization boosted this response more than ten-fold. The



345 subsequent third immunization showed a modest boost effect. At each of these study time  
346 points, there was no difference between the doses in C57BL/6 mice, while differences in  
347 BALB/c ID80 GMT were seen at week 2 (higher for the 10  $\mu$ g dose) and week 8 (higher for  
348 the 0.08  $\mu$ g dose). Overall, these studies demonstrated robust immunogenicity of four  
349 categories of SARS-CoV-2 S-domain ferritin nanoparticles.

350

### 351 **Protective Immunity in K18-hACE2 transgenic mice against SARS-CoV-2 Challenge**

352

353 Given the neutralizing antibody response seen with SpFN, and RFN, and the different  
354 design of these two immunogens, we chose to assess antibodies from these animals in a  
355 lethal SARS-CoV-2 challenge model using K18-hACE2 transgenic mice. The dose of SARS-  
356 CoV-2 virus was titrated to establish significant weight loss and pathology following  
357 infection with WA strain (Figure S6). Given previously described studies (Zheng et al.,  
358 2021), we sought to assess the vaccine-elicited antibody responses at levels starting at  
359 about 1,000 and we passively transferred three different amounts of purified IgG from  
360 either SpFN- or RFN-immunized mice 24 h prior to infection with SARS-CoV-2 (Figure 6A,  
361 6B). The control groups included a PBS group and a group that was passively transferred  
362 with naïve mouse IgG.

363 Animal weight was measured twice daily for 14 days after challenge, and animals  
364 that lost > 25% weight during the study were euthanized. All animals that received the  
365 highest amount of antibody (470  $\mu$ g SpFN-derived, or 370  $\mu$ g RFN-derived) showed  
366 neutralization ID<sub>50</sub> GMT titers of 1,713 and 1,179 respectively (Figure 6C). All animals in  
367 these two groups showed minimal weight loss (Figure 6D), and all animals survived the  
368 study (Figure 6E). In the two groups that received either 47  $\mu$ g SpFN- or 37  $\mu$ g RFN-derived  
369 antibody, neutralization ID<sub>50</sub> GMT titers were 89, and 248 respectively. Even with these  
370 modest antibody transfer amounts and the relatively low neutralization titers, most  
371 animals were protected from weight loss and death. In the SpFN-47  $\mu$ g group, only two  
372 animals showed severe weight loss, while in the RFN-37  $\mu$ g group, most animals showed  
373 some weight loss during the first study week, but all recovered. In contrast, mice that  
374 received the lowest amount of purified IgG from SpFN- or RFN-vaccinated animals, did not  
375 show any neutralizing antibody titers at the day of infection. The mice in these two groups  
376 showed significant weight loss, and 9/10 animals in each group were euthanized by day 9  
377 of the study. In a similar pattern, all animals from the naïve IgG and PBS groups suffered  
378 weight loss and were euthanized by study day 8. In summary, these data show that low  
379 amounts of passively transferred antibodies from SpFN or RFN vaccinated animals can  
380 protect mice from a lethal challenge with SARS-CoV-2.

381

### 382 **Vaccine-elicited broadly cross-reactive antibody responses against SARS-CoV-1 and** 383 **SARS-CoV-2**

384

385 SARS-CoV-2 variants that are more transmissible and appear to be more lethal continue to  
386 emerge even in the midst of rapid vaccine roll out and public-health measures. Given the  
387 robust binding, pseudovirus and authentic virus neutralization titers against the original  
388 SARS-CoV-2, that were elicited by the S-domain ferritin nanoparticle immunogens, we  
389 assessed the immunized mouse sera for binding and pseudovirus neutralization to the VoC  
390 (Figure 7). Using study week 10 sera from mice immunized with the four categories of

391 immunogens SpFN\_1B-06-PL, RFN\_131, pCoV146, and pCoV111 (S1-Ferritin), we assessed  
392 binding to a panel of variant RBD molecules containing K417N, E484K, N501Y, and  
393 combinations of these mutations (Figure 7A). These mutations match to the RBD sequence  
394 seen in the B.1.351, B.1.1.7, and P.1 SARS-CoV-2 strains. In all cases, robust binding to the  
395 RBD molecules were observed, with minimal change in overall binding when compared to  
396 the original RBD molecule. RFN-immunized mouse sera showed reduced binding to the  
397 E484K, N501Y double mutant, but increased binding to the K417N variant. Analysis of the  
398 sera from SpFN-, RFN, or pCoV111-immunized mice for pseudovirus neutralization of VoCs  
399 B.1.1.7 and B.1.351 showed minimal changes in the neutralization levels, with ID<sub>50</sub> values >  
400 2,000 for all strains (Figure 7B).

401 Analysis of the mouse sera for binding or neutralization of SARS-CoV-1 showed that  
402 RFN-immunized mice elicited the highest SARS-CoV-1 RBD binding response (Figure 7C).  
403 In addition, to RBD binding, we also observed SARS-CoV-1 ACE2-RBD inhibitory activity  
404 with the SpFN-immunized mice (Figure S5). We further assessed the SpFN- or RFN-  
405 immunized mouse sera for neutralization against SARS-CoV-1 using the pseudovirus assay  
406 (Figure 7D). We observed robust neutralization levels with ID<sub>50</sub> > 1,000 for the  
407 SpFN\_1B06-PL or the RFN\_131 immunized animals. In general, the RFN molecule elicited  
408 higher SARS-CoV-1 neutralizing responses compared to the SpFN-immunized animals.  
409 Together, these data demonstrate that the S-domain ferritin nanoparticles elicit broadly  
410 neutralizing and cross-reactive antibody responses against VoC and heterologous SARS-  
411 CoV-1.

## 412 413 **DISCUSSION**

414  
415 Since the emergence of SARS-CoV-2 in late 2019, multiple vaccines have been developed that  
416 elicit robust and protective immune responses in small animals, non-human primates, and  
417 humans. This includes a set of mRNA-based vaccines (NIH-Moderna Pfizer-BioNTech), viral  
418 vector vaccines (J&J, Astra Zeneca), and a nanoparticle-like vaccine (Novavax) (Bangaru et  
419 al., 2020) that are starting to be distributed worldwide, and include SARS-CoV-2 S as the  
420 major vaccine component. In addition, next generation SARS-CoV-2 vaccine candidates are  
421 beginning to reveal strong immunological results in pre-clinical studies (Saunders et al.,  
422 2021; Walls et al., 2020). These protein-based nanoparticle platforms paired with powerful  
423 adjuvant systems provide multiple advantages in the ability to protect against emerging  
424 variants (Moyo-Gwete et al., 2021; Wibmer et al., 2021). Nanoparticle vaccines may be  
425 critical for specific high-risk professions, or in populations where immune response titers  
426 are of particular importance (Atyeo et al., 2021) including the elderly (Collier et al., 2021) or  
427 immunocompromised (Boyarsky et al., 2021). The utility of highly stable vaccines that can  
428 elicit high neutralizing antibody titers after a single immunization, or vaccines that can be  
429 easily re-purposed for specific populations or as boosting immunogens is likely to help the  
430 long-term strategy for global COVID-19 vaccination.

431 Trimer-functionalized ferritin vaccines have been effective at eliciting neutralizing  
432 antibodies against class I fusion proteins, including influenza haemagglutinin (Kanekiyo et  
433 al., 2013; Kelly et al., 2020) and HIV envelope (He et al., 2016; Slieden et al., 2015) as well as  
434 engineered nanoparticles including RBD-12GS-I53-50 (Walls et al., 2020). For example, in  
435 the case of respiratory syncytial virus, a stabilized prefusion Fusion glycoprotein vaccine  
436 based on subtype A can naturally elicit potent neutralizing antibody and T cell responses

437 against the heterologous subtype B in animals and humans (Crank et al., 2019; Joyce et al.,  
438 2019). Here we developed a set of SARS-CoV-2 S-domain ferritin nanoparticle vaccines using  
439 structure-based vaccine design that recreate the structural and antigenic profile of S. These  
440 immunogens elicit antibodies with potent S-binding activity, hACE2-blocking activity, and  
441 potent neutralization activity against the homologous virus. In all four immunogen-design  
442 groups, antibody responses target the RBD domain and this response significantly  
443 contributes to the high neutralization responses. Additionally, dose-sparing immunization  
444 experiments show that significant antigen reduction can still elicit potent antibody  
445 responses, while simultaneously also showing robust levels of neutralizing antibodies  
446 against the heterologous SARS-CoV-1. This heterologous immune response is reminiscent of  
447 broad immune responses seen with Ferritin-HA immunogens (Kanekiyo et al., 2013), and  
448 demonstrate how nanoparticle immunogens can enhance the quality of the humoral immune  
449 response. Naturally occurring nanoparticle vaccines such as Yellow Fever 17D vaccine  
450 (Collins and Barrett, 2017) and human papillomavirus virus-like particle (VLP) vaccines  
451 (Lowy and Schiller, 2006) elicit robust and long-lived immune responses. For SARS-CoV-2  
452 vaccine development, nanoparticles performed well in mouse (Keech et al., 2020; Walls et  
453 al., 2020) and non-human primate studies (Brouwer et al., 2021), with a designed S-Ferritin  
454 nanoparticle also resulting in robust immunogenicity in mouse studies (Powell et al., 2021).

455 Furthermore, the passive-transfer of vaccine-elicited purified antibody prevented  
456 death and significant weight loss in a high-dose SARS-CoV-2 challenge in the K18-hACE2  
457 mouse model at neutralizing antibody levels that were routinely exceeded by SpFN- or RFN-  
458 vaccination. We also transferred very low amounts of antibody to the K18-hACE2 mice to  
459 assess for antibody dependent enhancement, and we saw no indication of faster weight loss,  
460 or enhanced symptoms in the mice. The fact that antibody amounts readily elicited after a  
461 single immunization are highly protective in this challenge model, and that low antibody  
462 levels do not enhance disease, highlights the promise of these vaccine candidates. A set of  
463 companion papers also maps out the cellular immune response and highlights the protective  
464 effect of SpFN and RFN in high-dose SARS-CoV-2 challenge studies (Joyce et al., 2021; King  
465 et al., 2021). Given the rapid elicitation of SARS-CoV-2 immune responses after a single  
466 immunization and the highly protective responses seen in the K18-hACE2 model, SpFN\_1B-  
467 06-PL has been produced under current Good Manufacturing Practice (cGMP) conditions  
468 and is under assessment in an ongoing phase I clinical trial (NCT04784767).

469 The immune responses elicited by the ferritin nanoparticles with the adjuvant ALFQ  
470 were consistently superior to that seen with the aluminum hydroxidebased Alhydrogel  
471 adjuvant. This result is consistent with other studies indicating that aluminum hydroxide is  
472 sub-optimal at inducing SARS-COV-2 neutralizing antibody responses [ref]. The  
473 components of the ALFQ adjuvant including QS-21, are used in multiple industrial  
474 processes and scaled up for future advanced clinical trials. The COVID-19 pandemic has set  
475 many precedents in regard to vaccine development speed, novel platforms, and should  
476 garner a new age of vaccine development utilizing advanced antigens and adjuvants to  
477 train the immune response for increased protection.

478 Here, we utilized structure-based design to create four categories of immunogens using the  
479 ferritin-nanoparticle platform. Each of these different designs and the underlying  
480 development processes provide a greater understanding and framework for ongoing and  
481 future pan-coronavirus vaccine design and development. The design information outlined  
482 here can be readily transferred for emerging CoV pathogens or other ubiquitous “common-

483 cold” coronaviruses. The utilization of the SARS-CoV-2 nanoparticle immunogen provided  
484 immunogenicity against variants of concern and the heterologous SARS-CoV-1 and has  
485 implications for vaccination efforts against putative zoonotic emergences.

486 **ACKNOWLEDGEMENTS**

487 We thank Sandhya Vasan, Mihret Amare, Suzanne Mate, Paul Scott, and Sharon P. Daye for  
488 programmatic support and planning, Nathaniel Jackson for cell culture maintenance; Erin  
489 Kavusak, and Jonah Heller for support with performance of the neutralization assays.  
490 Research was conducted in compliance with the Animal Welfare Act and other federal  
491 statutes and regulations relating to animals and experiments involving animals and  
492 adheres to principles stated in the *Guide for the Care and Use of Laboratory Animals*, NRC  
493 Publication, 1996 edition. This work was funded by the US Defense Health Agency, the US  
494 Department of the Army, and a cooperative agreement between The Henry M. Jackson  
495 Foundation for the Advancement of Military Medicine, Inc., and the US Department of  
496 Defense (W81XWH-18-2-0040). This study also was supported by grants from NIH (R01  
497 AI157155) J.B.C. is supported by a Helen Hay Whitney Foundation postdoctoral fellowship.  
498 Material has been reviewed by the Walter Reed Army Institute of Research. There is no  
499 objection to its presentation and/or publication. The views expressed are those of the  
500 authors and should not be construed to represent the positions of the U.S. Army or the  
501 Department of Defense.

502

503 **AUTHOR CONTRIBUTIONS**

504 M.G.J. and K.M. designed the study. M.G.J., P.V.T., and K.M. designed the immunogens. M.G.J.,  
505 W.-H.C., M.C., R.S.S., A.H., P.V.T., R.E.C. W.C.C., C.E.P., E.J.M., E.M., A.A., C.S., J.B.C., Y.L., A.A., J.K.,  
506 T.O., L.R., A.G., C.W., J.C., L.M.-R., C.K., N.G., Z.V., D.McC., Z.B., J.K., S.S., O.J., V.D., S.M., U.T.,  
507 C.B.K., M.Z., H.K., W.W., M.A.C., D.K.D., L.W.K., T.J.L., S.E.M., S.J.K., S.M., V.R.P., W.W.R., N.deV.,  
508 M.S.D., G.D.G., and M.Rao performed protein purification, biophysical assays, immunologic  
509 assays and animal studies. Z.B., M.Rao, G.R.M., and A.And. designed and provided the  
510 adjuvants. S.R., P.M.M. and M.T.E. provided the SR1-5 antibodies. M.G.J., W.H.C., R.S.S., A.H.,  
511 P.V.T., R.E.C., C.S., A.Ahm., L.W., Z.B., W.W., W.W.R., M.Ro., N.deV., M.S.D., G.D.G., M.Rao,  
512 N.L.M. and K.M. analyzed and interpreted the data. M.G.J. wrote the paper with assistance  
513 from all coauthors.

514

515 **DECLARATIONS OF INTERESTS**

516 M.G.J. and K.M. are named as inventors on International Patent Application No.  
517 WO/2021/21405 entitled "Vaccines against SARS-CoV-2 and other coronaviruses." M.G.J. is  
518 named as an inventor on International Patent Application No. WO/2018/081318 and U.S.  
519 patent 10,960,070 entitled "Prefusion Coronavirus Spike Proteins and Their Use." Z.B. is  
520 named as an inventor on U.S. patent 10,434,167 entitled "Non-toxic adjuvant formulation  
521 comprising a monophosphoryl lipid A (MPLA)-containing liposome composition and a  
522 saponin." Z.B. and G.R.M. are named inventors on "Compositions And Methods For Vaccine  
523 Delivery", US Patent Application: 16/607,917. M.S.D. is a consultant for Inbios, Vir  
524 Biotechnology, NGM Biopharmaceuticals and Carnival Corporation and on the Scientific  
525 Advisory Boards of Moderna and Immunome. The Diamond laboratory has received  
526 funding support in sponsored research agreements from Moderna, Vir Biotechnology and  
527 Emergent BioSolutions. S.R., P.M.M., and M.T.E. are employees of AstraZeneca and currently  
528 hold AstraZeneca stock or stock options. Zoltan Beck is currently employed at Pfizer.

529

## 530 REFERENCES

- 531
- 532 Bangaru, S., Ozorowski, G., Turner, H.L., Antanasijevic, A., Huang, D., Wang, X., Torres, J.L.,  
533 Diedrich, J.K., Tian, J.H., Portnoff, A.D., *et al.* (2020). Structural analysis of full-length SARS-  
534 CoV-2 spike protein from an advanced vaccine candidate. *Science* *370*, 1089-1094.
- 535 Barnes, C.O., West, A.P., Jr., Huey-Tubman, K.E., Hoffmann, M.A.G., Sharaf, N.G., Hoffman,  
536 P.R., Koranda, N., Gristick, H.B., Gaebler, C., Muecksch, F., *et al.* (2020). Structures of Human  
537 Antibodies Bound to SARS-CoV-2 Spike Reveal Common Epitopes and Recurrent Features  
538 of Antibodies. *Cell* *182*, 828-842 e816.
- 539 Boyarsky, B.J., Werbel, W.A., Avery, R.K., Tobian, A.A.R., Massie, A.B., Segev, D.L., and  
540 Garonzik-Wang, J.M. (2021). Immunogenicity of a Single Dose of SARS-CoV-2 Messenger  
541 RNA Vaccine in Solid Organ Transplant Recipients. *JAMA*.
- 542 Boyington, J.C., Joyce, M.G., Sastry, M., Stewart-Jones, G.B., Chen, M., Kong, W.P., Ngwuta, J.O.,  
543 Thomas, P.V., Tsybovsky, Y., Yang, Y., *et al.* (2016). Structure-Based Design of Head-Only  
544 Fusion Glycoprotein Immunogens for Respiratory Syncytial Virus. *PLoS One* *11*, e0159709.
- 545 Boyoglu-Barnum, S., Ellis, D., Gillespie, R.A., Hutchinson, G.B., Park, Y.-J., Moin, S.M., Acton,  
546 O., Ravichandran, R., Murphy, M., Pettie, D., *et al.* (2020). Elicitation of broadly protective  
547 immunity to influenza by multivalent hemagglutinin nanoparticle vaccines. *bioRxiv*,  
548 2020.2005.2030.125179.
- 549 Brouwer, P.J.M., Brinkkemper, M., Maisonnasse, P., Dereuddre-Bosquet, N., Grobber, M.,  
550 Claireaux, M., de Gast, M., Marlin, R., Chesnais, V., Diry, S., *et al.* (2021). Two-component  
551 spike nanoparticle vaccine protects macaques from SARS-CoV-2 infection. *Cell* *184*, 1188-  
552 1200 e1119.
- 553 Brouwer, P.J.M., Caniels, T.G., van der Straten, K., Snitselaar, J.L., Aldon, Y., Bangaru, S.,  
554 Torres, J.L., Okba, N.M.A., Claireaux, M., Kerster, G., *et al.* (2020). Potent neutralizing  
555 antibodies from COVID-19 patients define multiple targets of vulnerability. *Science* *369*,  
556 643-650.
- 557 Case, J.B., Rothlauf, P.W., Chen, R.E., Liu, Z., Zhao, H., Kim, A.S., Bloyet, L.M., Zeng, Q., Tahan,  
558 S., Droit, L., *et al.* (2020). Neutralizing Antibody and Soluble ACE2 Inhibition of a  
559 Replication-Competent VSV-SARS-CoV-2 and a Clinical Isolate of SARS-CoV-2. *Cell Host*  
560 *Microbe* *28*, 475-485 e475.
- 561 Cawfield, A., Genito, C.J., Beck, Z., Bergmann-Leitner, E.S., Bitzer, A.A., Soto, K., Zou, X.,  
562 Hadiwidjojo, S.H., Gerbasi, R.V., Mullins, A.B., *et al.* (2019). Safety, toxicity and  
563 immunogenicity of a malaria vaccine based on the circumsporozoite protein (FMP013)  
564 with the adjuvant army liposome formulation containing QS21 (ALFQ). *Vaccine* *37*, 3793-  
565 3803.
- 566 Cerutti, G., Guo, Y., Zhou, T., Gorman, J., Lee, M., Rapp, M., Reddem, E.R., Yu, J., Bahna, F.,  
567 Bimela, J., *et al.* (2021). Potent SARS-CoV-2 neutralizing antibodies directed against spike  
568 N-terminal domain target a single supersite. *Cell Host Microbe*.
- 569 Chen, X., Zhou, T., Schmidt, S.D., Duan, H., Cheng, C., Chuang, G.Y., Gu, Y., Louder, M.K., Lin,  
570 B.C., Shen, C.H., *et al.* (2021). Vaccination induces maturation in a mouse model of diverse  
571 unmutated VRC01-class precursors to HIV-neutralizing antibodies with >50% breadth.  
572 *Immunity* *54*, 324-339 e328.
- 573 Cohen, A.A., Gnanapragasam, P.N.P., Lee, Y.E., Hoffman, P.R., Ou, S., Kakutani, L.M., Keeffe,  
574 J.R., Wu, H.J., Howarth, M., West, A.P., *et al.* (2021). Mosaic nanoparticles elicit cross-reactive  
575 immune responses to zoonotic coronaviruses in mice. *Science* *371*, 735-741.

576 Collier, D.A., Ferreira, I.A.T.M., Datir, R., Meng, B., Bergamaschi, L., Elmer, A., Kingston, N.,  
577 Graves, B., Smith, K.G., Bradley, J.R., *et al.* (2021). Age-related heterogeneity in Neutralising  
578 antibody responses to SARS-CoV-2 following BNT162b2 vaccination. medRxiv,  
579 2021.2002.2003.21251054.

580 Collins, N.D., and Barrett, A.D. (2017). Live Attenuated Yellow Fever 17D Vaccine: A Legacy  
581 Vaccine Still Controlling Outbreaks In Modern Day. *Curr Infect Dis Rep* 19, 14.

582 Corbett, K.S., Edwards, D.K., Leist, S.R., Abiona, O.M., Boyoglu-Barnum, S., Gillespie, R.A.,  
583 Himansu, S., Schafer, A., Ziwawo, C.T., DiPiazza, A.T., *et al.* (2020). SARS-CoV-2 mRNA  
584 vaccine design enabled by prototype pathogen preparedness. *Nature* 586, 567-571.

585 Crank, M.C., Ruckwardt, T.J., Chen, M., Morabito, K.M., Phung, E., Costner, P.J., Holman, L.A.,  
586 Hickman, S.P., Berkowitz, N.M., Gordon, I.J., *et al.* (2019). A proof of concept for structure-  
587 based vaccine design targeting RSV in humans. *Science* 365, 505-509.

588 Cui, J., Li, F., and Shi, Z.L. (2019). Origin and evolution of pathogenic coronaviruses. *Nat Rev*  
589 *Microbiol* 17, 181-192.

590 Darricarrere, N., Qiu, Y., Kanekiyo, M., Creanga, A., Gillespie, R.A., Moin, S.M., Saleh, J.,  
591 Sancho, J., Chou, T.H., Zhou, Y., *et al.* (2021). Broad neutralization of H1 and H3 viruses by  
592 adjuvanted influenza HA stem vaccines in nonhuman primates. *Sci Transl Med* 13.

593 Duan, K., Liu, B., Li, C., Zhang, H., Yu, T., Qu, J., Zhou, M., Chen, L., Meng, S., Hu, Y., *et al.*  
594 (2020). Effectiveness of convalescent plasma therapy in severe COVID-19 patients. *Proc*  
595 *Natl Acad Sci U S A* 117, 9490-9496.

596 Greaney, A.J., Starr, T.N., Gilchuk, P., Zost, S.J., Binshtein, E., Loes, A.N., Hilton, S.K.,  
597 Huddleston, J., Eguia, R., Crawford, K.H.D., *et al.* (2021). Complete Mapping of Mutations to  
598 the SARS-CoV-2 Spike Receptor-Binding Domain that Escape Antibody Recognition. *Cell*  
599 *Host Microbe* 29, 44-57 e49.

600 Iyer, A.S., Jones, F.K., Nodoushani, A., Kelly, M., Becker, M., Slater, D., Mills, R., Teng, E.,  
601 Kamruzzaman, M., Garcia-Beltran, W.F., *et al.* (2020). Dynamics and significance of the  
602 antibody response to SARS-CoV-2 infection. medRxiv.

603 Jiang, S., Hillyer, C., and Du, L. (2020). Neutralizing Antibodies against SARS-CoV-2 and  
604 Other Human Coronaviruses. *Trends Immunol* 41, 355-359.

605 Joyce, M.G., Bao, A., Chen, M., Georgiev, I.S., Ou, L., Bylund, T., Druz, A., Kong, W.P., Peng, D.,  
606 Rundlet, E.J., *et al.* (2019). Crystal Structure and Immunogenicity of the DS-Cav1-Stabilized  
607 Fusion Glycoprotein From Respiratory Syncytial Virus Subtype B. *Pathog Immun* 4, 294-  
608 323.

609 Joyce, M.G., King, H.A.D., Elakhal Naouar, I., Ahmed, A., Peachman, K.K., Cincotta, C.M., Subra,  
610 C., Chen, R.E., Thomas, P.V., Chen, W.-H., *et al.* (2021). Efficacy of a Broadly Neutralizing  
611 SARS-CoV-2 Ferritin Nanoparticle Vaccine in Nonhuman Primates. bioRxiv,  
612 2021.2003.2024.436523.

613 Joyce, M.G., Sankhala, R.S., Chen, W.H., Choe, M., Bai, H., Hajduczki, A., Yan, L., Sterling, S.L.,  
614 Peterson, C.E., Green, E.C., *et al.* (2020). A Cryptic Site of Vulnerability on the Receptor  
615 Binding Domain of the SARS-CoV-2 Spike Glycoprotein. bioRxiv.

616 Kaba, S.A., Karch, C.P., Seth, L., Ferlez, K.M.B., Storme, C.K., Pesavento, D.M., Laughlin, P.Y.,  
617 Bergmann-Leitner, E.S., Burkhard, P., and Lanar, D.E. (2018). Self-assembling protein  
618 nanoparticles with built-in flagellin domains increases protective efficacy of a *Plasmodium*  
619 *falciparum* based vaccine. *Vaccine* 36, 906-914.

620 Kanekiyo, M., Bu, W., Joyce, M.G., Meng, G., Whittle, J.R., Baxa, U., Yamamoto, T., Narpala, S.,  
621 Todd, J.P., Rao, S.S., *et al.* (2015). Rational Design of an Epstein-Barr Virus Vaccine Targeting  
622 the Receptor-Binding Site. *Cell* *162*, 1090-1100.

623 Kanekiyo, M., Joyce, M.G., Gillespie, R.A., Gallagher, J.R., Andrews, S.F., Yassine, H.M.,  
624 Wheatley, A.K., Fisher, B.E., Ambrozak, D.R., Creanga, A., *et al.* (2019). Mosaic nanoparticle  
625 display of diverse influenza virus hemagglutinins elicits broad B cell responses. *Nat*  
626 *Immunol* *20*, 362-372.

627 Kanekiyo, M., Wei, C.J., Yassine, H.M., McTamney, P.M., Boyington, J.C., Whittle, J.R., Rao, S.S.,  
628 Kong, W.P., Wang, L., and Nabel, G.J. (2013). Self-assembling influenza nanoparticle  
629 vaccines elicit broadly neutralizing H1N1 antibodies. *Nature* *499*, 102-106.

630 Keech, C., Albert, G., Cho, I., Robertson, A., Reed, P., Neal, S., Pledsted, J.S., Zhu, M., Cloney-  
631 Clark, S., Zhou, H., *et al.* (2020). Phase 1-2 Trial of a SARS-CoV-2 Recombinant Spike Protein  
632 Nanoparticle Vaccine. *N Engl J Med* *383*, 2320-2332.

633 King, H.A.D., Gordon Joyce, M., Naouar, I.E., Ahmed, A., Cincotta, C.M., Subra, C., Peachman,  
634 K.K., Hack, H.H., Chen, R.E., Thomas, P.V., *et al.* (2021). Efficacy and breadth of adjuvanted  
635 SARS-CoV-2 receptor-binding domain nanoparticle vaccine in macaques. *bioRxiv*,  
636 2021.2004.2009.439166.

637 Kirchdoerfer, R.N., Cottrell, C.A., Wang, N., Pallesen, J., Yassine, H.M., Turner, H.L., Corbett,  
638 K.S., Graham, B.S., McLellan, J.S., and Ward, A.B. (2016). Pre-fusion structure of a human  
639 coronavirus spike protein. *Nature* *531*, 118-121.

640 Kong, R., Duan, H., Sheng, Z., Xu, K., Acharya, P., Chen, X., Cheng, C., Dingens, A.S., Gorman, J.,  
641 Sastry, M., *et al.* (2019). Antibody Lineages with Vaccine-Induced Antigen-Binding Hotspots  
642 Develop Broad HIV Neutralization. *Cell* *178*, 567-584 e519.

643 Lal, H., Cunningham, A.L., Godeaux, O., Chlibek, R., Diez-Domingo, J., Hwang, S.J., Levin, M.J.,  
644 McElhaney, J.E., Poder, A., Puig-Barbera, J., *et al.* (2015). Efficacy of an adjuvanted herpes  
645 zoster subunit vaccine in older adults. *N Engl J Med* *372*, 2087-2096.

646 Lan, J., Ge, J., Yu, J., Shan, S., Zhou, H., Fan, S., Zhang, Q., Shi, X., Wang, Q., Zhang, L., *et al.*  
647 (2020). Structure of the SARS-CoV-2 spike receptor-binding domain bound to the ACE2  
648 receptor. *Nature* *581*, 215-220.

649 Langowski, M.D., Khan, F.A., Bitzer, A.A., Genito, C.J., Schrader, A.J., Martin, M.L., Soto, K., Zou,  
650 X., Hadiwidjojo, S., Beck, Z., *et al.* (2020). Optimization of a Plasmodium falciparum  
651 circumsporozoite protein repeat vaccine using the tobacco mosaic virus platform. *Proc Natl*  
652 *Acad Sci U S A* *117*, 3114-3122.

653 Li, D., Edwards, R.J., Manne, K., Martinez, D.R., Schafer, A., Alam, S.M., Wiehe, K., Lu, X., Parks,  
654 R., Sutherland, L.L., *et al.* (2021). The functions of SARS-CoV-2 neutralizing and infection-  
655 enhancing antibodies in vitro and in mice and nonhuman primates. *bioRxiv*.

656 Liu, L., Wang, P., Nair, M.S., Yu, J., Rapp, M., Wang, Q., Luo, Y., Chan, J.F., Sahi, V., Figueroa, A.,  
657 *et al.* (2020). Potent neutralizing antibodies against multiple epitopes on SARS-CoV-2 spike.  
658 *Nature* *584*, 450-456.

659 Lowy, D.R., and Schiller, J.T. (2006). Prophylactic human papillomavirus vaccines. *J Clin*  
660 *Invest* *116*, 1167-1173.

661 Marcandalli, J., Fiala, B., Ols, S., Perotti, M., de van der Schueren, W., Snijder, J., Hodge, E.,  
662 Benhaim, M., Ravichandran, R., Carter, L., *et al.* (2019). Induction of Potent Neutralizing  
663 Antibody Responses by a Designed Protein Nanoparticle Vaccine for Respiratory Syncytial  
664 Virus. *Cell* *176*, 1420-1431 e1417.



665 Menachery, V.D., Yount, B.L., Jr., Debbink, K., Agnihothram, S., Gralinski, L.E., Plante, J.A.,  
666 Graham, R.L., Scobey, T., Ge, X.Y., Donaldson, E.F., *et al.* (2015). A SARS-like cluster of  
667 circulating bat coronaviruses shows potential for human emergence. *Nat Med* 21, 1508-  
668 1513.

669 Modjarrad, K., Roberts, C.C., Mills, K.T., Castellano, A.R., Paolino, K., Muthumani, K.,  
670 Reuschel, E.L., Robb, M.L., Racine, T., Oh, M.D., *et al.* (2019). Safety and immunogenicity of  
671 an anti-Middle East respiratory syndrome coronavirus DNA vaccine: a phase 1, open-label,  
672 single-arm, dose-escalation trial. *Lancet Infect Dis* 19, 1013-1022.

673 Moyo-Gwete, T., Madzivhandila, M., Makhado, Z., Ayres, F., Mhlanga, D., Oosthuysen, B.,  
674 Lambson, B.E., Kgagudi, P., Tegally, H., Iranzadeh, A., *et al.* (2021). SARS-CoV-2 501Y.V2  
675 (B.1.351) elicits cross-reactive neutralizing antibodies. *bioRxiv*.

676 Om, K., Paquin-Proulx, D., Montero, M., Peachman, K., Shen, X., Wiczorek, L., Beck, Z.,  
677 Weiner, J.A., Kim, D., Li, Y., *et al.* (2020). Adjuvanted HIV-1 vaccine promotes antibody-  
678 dependent phagocytic responses and protects against heterologous SHIV challenge. *PLoS*  
679 *Pathog* 16, e1008764.

680 Pallesen, J., Wang, N., Corbett, K.S., Wrapp, D., Kirchdoerfer, R.N., Turner, H.L., Cottrell, C.A.,  
681 Becker, M.M., Wang, L., Shi, W., *et al.* (2017). Immunogenicity and structures of a rationally  
682 designed prefusion MERS-CoV spike antigen. *Proc Natl Acad Sci U S A* 114, E7348-E7357.

683 Pati, R., Shevtsov, M., and Sonawane, A. (2018). Nanoparticle Vaccines Against Infectious  
684 Diseases. *Front Immunol* 9, 2224.

685 Piehler, B., Nelson, E.K., Eckels, J., Ramsay, S., Lum, K., Wood, B., Greene, K.M., Gao, H.,  
686 Seaman, M.S., Montefiori, D.C., *et al.* (2011). LabKey Server NAb: a tool for analyzing,  
687 visualizing and sharing results from neutralizing antibody assays. *BMC Immunol* 12, 33.

688 Pinto, D., Park, Y.J., Beltramello, M., Walls, A.C., Tortorici, M.A., Bianchi, S., Jaconi, S., Culap,  
689 K., Zatta, F., De Marco, A., *et al.* (2020). Cross-neutralization of SARS-CoV-2 by a human  
690 monoclonal SARS-CoV antibody. *Nature* 583, 290-295.

691 Plotkin, S.A. (2017). Vaccines for epidemic infections and the role of CEPI. *Hum Vaccin*  
692 *Immunother* 13, 2755-2762.

693 Powell, A.E., Zhang, K., Sanyal, M., Tang, S., Weidenbacher, P.A., Li, S., Pham, T.D., Pak, J.E.,  
694 Chiu, W., and Kim, P.S. (2021). A Single Immunization with Spike-Functionalized Ferritin  
695 Vaccines Elicits Neutralizing Antibody Responses against SARS-CoV-2 in Mice. *ACS Cent Sci*  
696 7, 183-199.

697 Rappazzo, C.G., Tse, L.V., Kaku, C.I., Wrapp, D., Sakharkar, M., Huang, D., Deveau, L.M.,  
698 Yockachonis, T.J., Herbert, A.S., Battles, M.B., *et al.* (2021). Broad and potent activity against  
699 SARS-like viruses by an engineered human monoclonal antibody. *Science* 371, 823-829.

700 Salazar, E., Christensen, P.A., Graviss, E.A., Nguyen, D.T., Castillo, B., Chen, J., Lopez, B.V.,  
701 Eagar, T.N., Yi, X., Zhao, P., *et al.* (2020). Treatment of Coronavirus Disease 2019 Patients  
702 with Convalescent Plasma Reveals a Signal of Significantly Decreased Mortality. *Am J Pathol*  
703 190, 2290-2303.

704 Sauer, M.M., Tortorici, M.A., Park, Y.-J., Walls, A.C., Homad, L., Acton, O., Bowen, J., Wang, C.,  
705 Xiong, X., de van der Schueren, W., *et al.* (2021). Structural basis for broad coronavirus  
706 neutralization. *bioRxiv*, 2020.2012.2029.424482.

707 Saunders, K.O., Lee, E., Parks, R., Martinez, D.R., Li, D., Chen, H., Edwards, R.J., Gobeil, S., Barr,  
708 M., Mansouri, K., *et al.* (2021). SARS-CoV-2 vaccination induces neutralizing antibodies  
709 against pandemic and pre-emergent SARS-related coronaviruses in monkeys. *bioRxiv*,  
710 2021.2002.2017.431492.

711 Shen, C., Wang, Z., Zhao, F., Yang, Y., Li, J., Yuan, J., Wang, F., Li, D., Yang, M., Xing, L., *et al.*  
712 (2020). Treatment of 5 Critically Ill Patients With COVID-19 With Convalescent Plasma.  
713 JAMA 323, 1582-1589.

714 ter Meulen, J., van den Brink, E.N., Poon, L.L., Marissen, W.E., Leung, C.S., Cox, F., Cheung,  
715 C.Y., Bakker, A.Q., Bogaards, J.A., van Deventer, E., *et al.* (2006). Human monoclonal  
716 antibody combination against SARS coronavirus: synergy and coverage of escape mutants.  
717 PLoS Med 3, e237.

718 Tian, X., Li, C., Huang, A., Xia, S., Lu, S., Shi, Z., Lu, L., Jiang, S., Yang, Z., Wu, Y., *et al.* (2020).  
719 Potent binding of 2019 novel coronavirus spike protein by a SARS coronavirus-specific  
720 human monoclonal antibody. Emerg Microbes Infect 9, 382-385.

721 Turonova, B., Sikora, M., Schurmann, C., Hagen, W.J.H., Welsch, S., Blanc, F.E.C., von Bulow,  
722 S., Gecht, M., Bagola, K., Horner, C., *et al.* (2020). In situ structural analysis of SARS-CoV-2  
723 spike reveals flexibility mediated by three hinges. Science 370, 203-208.

724 Ueda, G., Antanasijevic, A., Fallas, J.A., Sheffler, W., Copps, J., Ellis, D., Hutchinson, G.B.,  
725 Moyer, A., Yasmeen, A., Tsybovsky, Y., *et al.* (2020). Tailored design of protein nanoparticle  
726 scaffolds for multivalent presentation of viral glycoprotein antigens. Elife 9.

727 Walls, A.C., Fiala, B., Schafer, A., Wrenn, S., Pham, M.N., Murphy, M., Tse, L.V., Shehata, L.,  
728 O'Connor, M.A., Chen, C., *et al.* (2020). Elicitation of Potent Neutralizing Antibody  
729 Responses by Designed Protein Nanoparticle Vaccines for SARS-CoV-2. Cell 183, 1367-1382  
730 e1317.

731 Walls, A.C., Tortorici, M.A., Bosch, B.J., Frenz, B., Rottier, P.J.M., DiMaio, F., Rey, F.A., and  
732 Veesler, D. (2016). Cryo-electron microscopy structure of a coronavirus spike glycoprotein  
733 trimer. Nature 531, 114-117.

734 Wang, L., Shi, W., Joyce, M.G., Modjarrad, K., Zhang, Y., Leung, K., Lees, C.R., Zhou, T., Yassine,  
735 H.M., Kanekiyo, M., *et al.* (2015). Evaluation of candidate vaccine approaches for MERS-CoV.  
736 Nat Commun 6, 7712.

737 Wang, L., Zhou, T., Zhang, Y., Yang, E.S., Schramm, C.A., Shi, W., Pegu, A., Oloninyi, O.K.,  
738 Ransier, A., Darko, S., *et al.* (2021). Antibodies with potent and broad neutralizing activity  
739 against antigenically diverse and highly transmissible SARS-CoV-2 variants. bioRxiv.

740 Wibmer, C.K., Ayres, F., Hermanus, T., Madzivhandila, M., Kgagudi, P., Oosthuysen, B.,  
741 Lambson, B.E., de Oliveira, T., Vermeulen, M., van der Berg, K., *et al.* (2021). SARS-CoV-2  
742 501Y.V2 escapes neutralization by South African COVID-19 donor plasma. Nat Med.

743 Wrapp, D., De Vlioger, D., Corbett, K.S., Torres, G.M., Wang, N., Van Breedam, W., Roose, K.,  
744 van Schie, L., Team, V.-C.C.-R., Hoffmann, M., *et al.* (2020). Structural Basis for Potent  
745 Neutralization of Betacoronaviruses by Single-Domain Camelid Antibodies. Cell 181, 1004-  
746 1015 e1015.

747 Zheng, J., Wong, L.R., Li, K., Verma, A.K., Ortiz, M.E., Wohlford-Lenane, C., Leidinger, M.R.,  
748 Knudson, C.M., Meyerholz, D.K., McCray, P.B., Jr., *et al.* (2021). COVID-19 treatments and  
749 pathogenesis including anosmia in K18-hACE2 mice. Nature 589, 603-607.

750 Zost, S.J., Gilchuk, P., Case, J.B., Binshtein, E., Chen, R.E., Nkolola, J.P., Schafer, A., Reidy, J.X.,  
751 Trivette, A., Nargi, R.S., *et al.* (2020). Potently neutralizing and protective human antibodies  
752 against SARS-CoV-2. Nature 584, 443-449.

753  
754  
755

## STAR METHODS

756 Detailed methods are provided in the online version of this paper and include the  
757 following:

758

759 **KEY RESOURCES TABLE**

760 **RESOURCE AVAILABILITY**

761       Lead contact

762       Materials availability

763       Data and code availability statement

764 **METHOD DETAILS**

765       Immunogen Modeling and Design

766       DNA plasmid construction and preparation

767       Protein expression and purification

768       Negative-stain Electron microscopy

769       Octet Biolayer Interferometry binding and ACE2 inhibition assays

770       Mouse immunization

771       Immunogen-Adjuvant preparations

772       Enzyme Linked Immunosorbent Assay

773       SARS-CoV-2 and SARS-CoV-1 pseudovirus neutralization assay

774       Authentic SARS-CoV-2 virus neutralization assay

775       K18-hACE2 transgenic mouse passive immunization and challenge

776

777 **QUANTIFICATION AND STATISTICAL ANALYSIS**

778

779 **RESOURCE AVAILABILITY**

780

781 **Lead contact**

782 Further information and requests for resources and reagents should be directed to and will  
783 be fulfilled by the Lead Contact, M. Gordon Joyce ([gjoyce@eidresearch.org](mailto:gjoyce@eidresearch.org)).

784

785 **Materials Availability**

786 All reagents will be made available on request after completion of a Materials Transfer  
787 Agreement.

788

789 **Data and Code Availability**

790 All data supporting the findings of this study are found within the paper and its  
791 Supplementary Information and are available from the Lead Contact author upon request.

792

793 **Figure legends**

794 **Figure 1. Structure-based design of SARS-CoV-2 S-based ferritin nanoparticle**

795 **immunogens**

796 (A) Full length SARS-CoV-2 S schematic and 3D-structure. S hinges identified by molecular  
797 dynamics simulations and electron cryotomography are labeled on the 3D- model  
798 ((Turonova et al., 2020). The structured trimeric ectodomain is colored according to the  
799 schematic with the N-terminal domain (NTD) and Receptor-Binding Domain (RBD) of the  
800 S1 polypeptide and the C-terminal coiled coil N-terminal to hinge 1 colored blue, green, and  
801 purple, respectively. Remaining portions of the S1 and S2 polypeptides are colored in red

802 and cyan with regions membrane-proximal from hinge 2 colored in white. The  
803 transmembrane domain of all chains is depicted in yellow. To design a Spike-Ferritin  
804 molecule, the C-terminal heptad repeat (residues 1140 to 1161) between Hinge 1 and 2  
805 were aligned to an ideal heptad repeat sequence. Residues in the native S sequence which  
806 break this pattern are highlighted in red. These residues are also labeled and highlighted in  
807 red on the 3D-structure. Two engineered designs (1B-05 and 1B-06) are shown, with S end  
808 residue used to link to Ferritin, and heptad-repeat mutations colored green.

809 (B) Schematic and 3D model of Spike Ferritin nanoparticle (SpFN). Differences between the  
810 native S sequence and the engineered nanoparticle are indicated on the schematic. A 3D-  
811 model of SpFN displaying eight trimeric Spikes was created using PDB ID 6VXX and 3EGM  
812 with the ferritin molecule shown in alternating grey and white. The nanoparticle is  
813 depicted along the 4-fold and the 3-fold symmetry axes of the ferritin.

814 (C) RBD–Ferritin nanoparticle design and optimization. The RBD of SARS-CoV-2 (PDB  
815 ID:6MOJ) is shown in surface representation, with the ACE2 binding site outlined in dashed  
816 lines. Three hydrophobic regions of the RBD which were mutated for nanoparticle  
817 immunogen design are shown in light green surface, with residues in stick representation.  
818 The ACE2 binding site contains two of these regions, while a third hydrophobic patch near  
819 the C-terminus of the RBD is typically buried by S2 and part of S1 in the context of the  
820 trimer molecule.

821 (D) Schematic and 3D model of an RBD–Ferritin nanoparticle. A modeled 24-mer  
822 nanoparticle displaying the RBD domain is depicted at the 3-fold symmetry axis of ferritin  
823 and colored green. Truncation points, linkers, and alterations made to the RBD sequence  
824 are indicated on the schematic.

825 (E) Schematic and 3D model of an RBD–NTD–Ferritin nanoparticle. A modeled nanoparticle  
826 displaying RBD and NTD epitopes is depicted and colored according to the schematic.  
827 Truncation points, linkers, and alterations made to the native S sequence are indicated on  
828 the primary structure.

829 (F) S1-Ferritin immunogen design. The SARS-CoV-2 S1 forms a hydrophobic collar around  
830 the N-terminal  $\beta$ -sheet of S2 (residues 689-676). S1-ferritin immunogen design required  
831 inclusion of this short stretch of S2 (colored cyan) attached by a linker. Terminal residues  
832 of the structured portions of S1 and S2 are labeled.

833 (G) Schematic and 3D model of an S1–Ferritin nanoparticle. A modeled nanoparticle  
834 displaying RBD and NTD domains is depicted and colored according to the S1–ferritin  
835 schematic with truncation points and domain linkers indicated. See also Figure S1 and  
836 Table S1.

837

## 838 **Figure 2. Antigenic and biophysical characterization of SARS-CoV-2 Spike-based** 839 **ferritin nanoparticle vaccine candidates**

840 SDS-PAGE of (A) Spike-Ferritin nanoparticle designs, (B) Receptor-binding domain-Ferritin  
841 nanoparticle designs, (C) S1-ferritin nanoparticle, and (D) RBD-NTD-Ferritin nanoparticles.  
842 Molecular weight standards are indicated in kDa.

843 (E) Size-exclusion chromatography on a Superdex S200 10/300 column of representative  
844 SARS-CoV-2 S-based ferritin nanoparticles. (F) Negative-stain electron microscopy 2D class  
845 averages of purified nanoparticles. The black bars represent 50 nm. See also Figure S2 and  
846 S3.

847

848 **Figure 3. Antigenic characterization of select SARS-CoV-2 Spike-based ferritin**  
849 **nanoparticle vaccine candidates**

850 Binding response of SARS-CoV-2 neutralizing antibodies to each of the lead candidates  
851 from the four design categories measured by biolayer interferometry with two-fold serial  
852 dilution of each antibody starting at 30 µg/ml).

853 (A) Spike-Ferritin nanoparticle SpFN\_1B-06-PL.

854 (B) RBD-Ferritin pCoV131.

855 (C) RBD-NTD-Ferritin nanoparticle pCoV146.

856 (D) S1-Ferritin nanoparticle pCoV111.

857 See also Figure S3.

858

859 **Figure 4. Negative-Stain Electron Microscopy 3D Reconstructions of SARS-CoV-2**  
860 **Spike Domain-Ferritin Nanoparticles**

861 Modifications made to native sequence and linkers used for each construct are shown in  
862 schematic diagrams.

863 (A) Negative-stain 3D reconstructions with applied octahedral symmetry are shown with  
864 an asymmetric unit of non-ferritin density colored and the size of each particle indicated in  
865 nanometers. Spike trimer density, is colored in red, and a model of a SpFN trimer based on  
866 PDB 6VXX is shown docked into the negative-stain map and colored according to the  
867 sequence diagram.

868 (B) Two non-ferritin densities per asymmetric unit were observed for RFN and are  
869 highlighted in green. These densities putatively correspond to the receptor-binding domain  
870 (RBD) but lack low resolution distinguishing features due to the small, globular shape of  
871 these domains. The presence of two densities is likely due to flexibility in the linker and  
872 heterogeneity in the RBD pose.

873 (C) Two layers of densities were distinguishable for pCoV146, with the putative N-terminal  
874 domain (NTD) density of an asymmetric unit colored blue, proximal to the ferritin and two  
875 smaller, more flexible densities corresponding to RBD distal to the ferritin and colored  
876 green.

877 (D) An asymmetric unit of non-ferritin density for pCoV111 is colored in orange and a  
878 monomer of S1 in the closed trimer state from PDB 6VXX is shown docked into the density  
879 with domains colored as in the sequence diagram.

880 See also Figure S2 and Table S2.

881

882 **Figure 5 SARS-CoV-2 Spike-domain nanoparticle vaccine candidates elicit robust**  
883 **binding and neutralizing antibody responses in mice.**

884 (A) Biolayer interferometry binding of mouse sera to SARS-COV-2 RBD. Study week is  
885 indicated on the base of the graph. Mean value is indicated by a horizontal line. Statistical  
886 comparison at each timepoint was carried out using a a Kruskal-Wallis test followed by a  
887 Dunn's post-test.

888 (B) ELISA binding of mouse sera to SARS-COV-2 S-2P or RBD. Study week is indicated on  
889 the base of the graph. Geometric mean value is indicated by a horizontal line. Statistical  
890 comparison at each timepoint was carried out using a a Kruskal-Wallis test followed by a  
891 Dunn's post-test.

892 (C) SARS-CoV-2 pseudovirus neutralization ID<sub>50</sub> and ID<sub>80</sub> values. Geometric mean value is  
893 indicated by a horizontal line. Statistical comparisons at each given timepoint was carried  
894 out using a Kruskal-Wallis test followed by a Dunn's post-test.

895 (D) Binding and pseudovirus neutralization of sera from mice immunized with 0.08 µg  
896 SpFN + ALFQ.

897 (E) Authentic SARS-CoV-2 virus strain 2019-nCoV/USA\_WA1/2020 neutralization ID<sub>50</sub>  
898 and ID<sub>80</sub> are shown for mice immunized with 10 or 0.08 µg SpFN + ALFQ. Geometric mean  
899 value is indicated by a horizontal line. Comparisons between dose group at each time point  
900 were carried out using a Mann-Whitney unpaired two-tailed non-parametric test, n=10  
901 mice/group.

902 In panels A – C, all immunogen groups at a given study timepoint were compared to each  
903 other. Only groups with statistically significant differences are indicated by a bar; all other  
904 groups did not show statistically significant differences. P values <0.0001 (\*\*\*\*), <0.001  
905 (\*\*\*), <0.01 (\*\*), or <0.05 (\*).

906 See also Figure S4 and S5, and Table S3 and S4.

907

908 **Figure 6. SpFN- and RBD-FN protective immunity in K18-hACE2 transgenic mice.**

909 (A) IgG was purified from SPFN- or RFN-vaccinated mouse sera and passively transferred  
910 at specific IgG amounts ranging from 4 - 470 µg/mouse in a final volume of 200 µl. Control  
911 naïve mouse IgG was formulated at 2 mg/ml. (n=10/group, 5 female, 5 male).

912 (B) Mouse challenge study schematic. K18-hACE2 mice (n=10/group, 5 female, 5 male)  
913 received control IgG (black), PBS (gray), and purified IgG, one day prior to challenge with  
914  $1.25 \times 10^4$  PFU of SARS-CoV-2.

915 (C) SARS-CoV-2 pseudovirus neutralization ID<sub>50</sub> titers of mouse sera at study day 0.

916 (D) Percentage of initial weight of K18-hACE2 mice for the 8 study groups. Legend is shown  
917 in panel E.

918 (E) Survival curves of K18-hACE2 mice with groups indicated based on animal vaccination  
919 group and the pseudovirus ID<sub>50</sub> neutralization values. Statistical comparisons were carried  
920 out using Mantel-Cox test followed by Bonferroni correction.

921 See also Figure S6.

922

923 **Figure 7. SARS-CoV-2 Spike-domain nanoparticle vaccine candidates elicit robust  
924 antibody binding responses and neutralizing activity against SARS-CoV-2 VoC and  
925 SARS-CoV-1.**

926 (A) Biolayer Interferometry binding of study week 10 immunized C57BL/6 mouse serum  
927 to SARS-CoV-2 RBD, and SARS-CoV-2 RBD variants. Immunogens are indicated at the top  
928 left of each graph. Mean values are indicated by a horizontal line, n=10, Significance was  
929 assessed using a Kruskal-Wallis test followed by a Dunn's post-test.

930 (B) Pseudovirus neutralization (ID<sub>50</sub> values) of study week 10 immunized C57BL/6 and  
931 BALB/c mouse serum to SARS-CoV-2 Wuhan-1, B.1.1.7, and B.1.351 pseudotyped viruses.  
932 Immunogens are indicated at the base of each graph. Geometric mean values are indicated  
933 by a horizontal line, n=5, statistical significance for each immunogen was assessed using a  
934 Kruskal-Wallis test followed by a Dunn's post-test.

935 (C) Biolayer Interferometry binding of study week 10 immunized C57BL/6 and BALB/c  
936 mouse serum to SARS-CoV-1 RBD. Immunogens are indicated at the base of each graph.

937 Mean values are indicated by a horizontal line, n=10, Significance was assessed using a  
938 Kruskal-Wallis test followed by a Dunn's post-test.  
939 (D) Pseudovirus neutralization (ID<sub>50</sub> values) of study week 10 immunized C57BL/6 and  
940 BALB/c mouse serum to SARS-CoV-1 Urbani strain pseudotyped viruses. Data related to  
941 SpFN and RFN are colored blue and green respectively. Statistical comparisons between  
942 SpFN and RFN responses at each time point were carried out using a Mann-Whitney  
943 unpaired two-tailed non-parametric test.  
944 Immunogens are indicated at the base of each graph. Geometric mean values are indicated  
945 by a horizontal line, n=10, P values <0.0001 (\*\*\*\*), <0.01 (\*\*) or <0.05 (\*).  
946 See also Figure S4 and S5.

947

#### 948 **List of supplementary figures.**

#### 949 **Figure S1. Structure-based design of SARS-CoV-2 Spike-based ferritin nanoparticle** 950 **immunogens and design pipeline, related to Figure 1.**

951 Four ferritin nanoparticle immunogen designs were developed focused on (1) Spike  
952 ferritin nanoparticles (blue), (2) RBD ferritin nanoparticles (green), (3) RBD-NTD ferritin  
953 nanoparticles (black), and (4) S1 ferritin nanoparticles (orange). The design iterations and  
954 concepts are indicated, along with select mutations and design name. Lead vaccine  
955 candidates from each category are highlighted.

956

#### 957 **Figure S2. Negative-stain electron microscopy 2D micrographs of SARS-CoV-2 ferritin** 958 **nanoparticle-based vaccine candidates, related to Figure 2 and 4.**

959 Negative-stain electron microscopy 2D micrographs. The white scale bars represent 100  
960 nm.

961 (A) Spike ferritin nanoparticles pCoV1B-05 and pCoV1B-08.

962 (B) RBD ferritin nanoparticles pCoV03, pCoV50, pCoV58, pCoV59, pCoV127, pCoV129,  
963 pCoV130, pCoV131

964 (C) RBD-NTD ferritin nanoparticles pCoV122, pCoV125, pCoV147

965 (D) S1 ferritin nanoparticle pCoV110 and pCoV112.

966

#### 967 **Figure S3. Biophysical and antigenic characterization of S-domain ferritin** 968 **nanoparticle immunogens, related to Figure 2 and 3.**

969 (A) Size-exclusion chromatography on a Superdex S200 10/300 column of representative  
970 SARS-CoV-2 Spike-based ferritin nanoparticles from the four design categories.

971 (B) Expression levels (mg/L supernatant) of representative SARS-CoV-2 Spike-based  
972 ferritin nanoparticles.

973 (C) Dynamic light scattering analysis of representative SARS-CoV-2 Spike-based ferritin  
974 nanoparticles.

975 (D) Spike ferritin nanoparticles (E) RBD ferritin, (F) RBD-NTD ferritin and (G) S1 ferritin  
976 nanoparticles were assessed for binding to a set of neutralizing antibodies (concentration =  
977 30 µg/ml) by biolayer interferometry.

978

#### 979 **Figure S4 SARS-CoV-2 nanoparticle vaccine candidates elicit robust binding and** 980 **pseudovirus neutralizing antibody responses in mice. Related to Figure 5 and 7.**

981 (A) Biolayer Interferometry binding analysis of C57BL/6 and BALB/c sera from mice  
982 immunized with SpFN + Alhydrogel® (B) RFN + Alhydrogel® and (C) pCoV146 +  
983 Alhydrogel® to SARS-CoV-2 RBD. Mean values are indicated by a horizontal line, n=10.  
984 (D) Pseudovirus neutralization (ID<sub>50</sub> values) of C57BL/6 and BALB/c sera from mice  
985 immunized with SpFN + Alhydrogel® (E) RFN + Alhydrogel® and (F) pCoV146 +  
986 Alhydrogel®. Geometric mean values are indicated by a horizontal line, n=10.  
987 (G) ELISA analysis of antibody isotype usage following immunization with SpFN + ALFQ  
988 (solid shapes), or SpFN + Alhydrogel® (open shapes). Sera collected study week 2, 5, and 8  
989 from immunized mice were added in quadruplicate serial dilutions to ELISA plates coated  
990 with S-2P protein. Duplicated wells were probed with anti-mouse-IgG1-HRP. Additional  
991 duplicates were probed with either anti-mouse-IgG2c-HRP or anti-mouse IgG2a-HRP for  
992 C57BL/6 and BALB/c mice, respectively. Data was interpolated to obtain the dilution factor  
993 at OD<sub>450</sub> of 1 and plotted as ratios of IgG2/IgG1. A horizontal dotted line denotes a  
994 balanced 1:1 IgG2/IgG1 ratio. Isotype ratio values were compared between the two  
995 adjuvant groups at each timepoint for each mouse type using a Mann-Whitney unpaired  
996 two-tailed non-parametric test.  
997 (H) Biolayer interferometry analysis of BALB/c mouse sera binding to SARS-CoV-2 RBD at  
998 study weeks 2, 5 and 8. Mice were immunized with the four lead candidate vaccines SpFN  
999 (blue), RFN (green), pCoV146 (black) and pCOV111 (orange). Binding mean values are  
1000 indicated by a horizontal line, n=10, sera responses at a given study week were compared  
1001 for statistical differences using a Kruskal-Wallis test followed by a Dunn's post-test.  
1002 (I) ELISA analysis of BALB/c mice immune responses as indicated in (H). Binding  
1003 geometric mean values of the endpoint titers are indicated by a horizontal line, n=10, sera  
1004 responses at a given study week were compared for statistical differences using a Kruskal-  
1005 Wallis test followed by a Dunn's post-test.  
1006 (J) Pseudovirus neutralization ID<sub>50</sub> titers of BALB/c mice immunized as indicated in (H).  
1007 Geometric mean values are indicated by a horizontal line, n=10, sera neutralization titers at  
1008 a given study week for the four immunogens were compared for statistical differences  
1009 using a Kruskal-Wallis test followed by a Dunn's post-test.  
1010 (K) Pseudovirus neutralization ID<sub>80</sub> titers of C57BL/6 (left) and BALB/c mice (right)  
1011 immunized as indicated in (H). Geometric mean values are indicated by a horizontal line,  
1012 n=10, sera neutralization titers at a given study week for the four immunogens were  
1013 compared for statistical differences using a Kruskal-Wallis test followed by a Dunn's post-  
1014 test.  
1015 P values <0.0001 (\*\*\*\*), <0.001 (\*\*\*), <0.01 (\*\*) or <0.05 (\*).

1016  
1017 **Figure S5 SARS-CoV-2 SpFN vaccine candidate elicits robust binding and neutralizing**  
1018 **antibody responses at reduced doses in mice. Related to Figure 5 and 7.**

1019 (A) Biolayer interferometry analysis of C57BL/6 and (B) BALB/c mouse sera binding  
1020 response to SARS-CoV-2 RBD following immunization with reducing doses of SpFN.  
1021 (C, E) ELISA analysis of C57BL/6 and (D, F) BALB/c mouse sera binding response to SARS-  
1022 CoV-2 RBD or S-2P following immunization with reducing doses of SpFN.  
1023 (G) SARS-CoV-2 pseudovirus ID<sub>80</sub> neutralization titers of mice immunized with 0.08 µg  
1024 SpFN + ALFQ.  
1025 (H) Authentic SARS-CoV-2 virus ID<sub>80</sub> neutralization titers of mice immunized with 10 µg  
1026 (blue) or 0.08 µg (light blue) SpFN + ALFQ. Geometric mean titers for each group and time



1027 point are indicated by a horizontal line, n =10. Neutralization titers for the two dose  
1028 groups at each study time point were compared for statistically significant differences  
1029 using a Mann-Whitney unpaired two-tailed non-parametric test. The two BALB/c time  
1030 points that showed differences are indicated by bars. P values <0.001 (\*\*\*), <0.01 (\*\*).  
1031 (I) Mouse sera from study week 10 was analyzed for hACE2 blocking capacity to SARS-CoV-  
1032 2 RBD (left) or SARS-CoV-1 RBD using a biolayer interferometry assay format.  
1033

1034 **Figure S6 Histopathological analysis of SARS-CoV-2 infection in K18-ACE2 mice.**  
1035 **Related to Figure 7**

1036 (A, B) Hematoxylin and eosin staining of lung sections from K18-hACE2 mice following  
1037 intranasal infection with  $1.25 \times 10^4$  PFU SARS-CoV-2. Images show two magnifications.  
1038 Images are representative of n = 10 per group.  
1039  
1040

1041 **Table S1. Spike-domain ferritin immunogens**  
1042

Spike-Ferritin (all based on S-2P variant with $\Delta$ furin and PP)			
Construct ID	Description		
pCoV1B-01	S2P(1-1137)-del-4-Ferritin	Shortened ectodomain - no coiled coil (closest to flu HA pass off)	NL
pCoV1B-02	S2P(1-1137)-del-6-Ferritin	Shortened ectodomain - no coiled coil (closest to flu HA pass off)	NL
pCoV1B-03	S2P(1-1208)-del-Ferritin	Full ectodomain	NL
pCoV1B-04	S2P(1-1208)-GCN4-Ferritin	Full ectodomain with GCN4	NL
pCoV1B-05	S2P(1-1154)-del-Ferritin	Shortened ectodomain with ending with a couple turns of coiled coil	NL
pCoV1B-06	S2P(1-1158)op1-del-Ferritin	Optimized HR ending (end on glycan N1158)	NL
pCoV1B-07	S2P(1-1158)op2-del-Ferritin	Optimized HR ending (Ile) (end on glycan N1158)	NL
pCoV1B-08	S2P(1-1158)op1x2-del-Ferritin	Optimized HR ending (N1158 glycan removed, but exists on the repeated HR)	NL
pCoV1B-09	S2P(1-1158)op2x2-del-Ferritin	Optimized HR ending (Ile) (N1158 glycan removed, but exists on the repeated HR)	NL
pCoV1B-10	S2P(1-1158)op1-fGCN4-del-Ferritin	Optimized HR ending with GCN4 fused in register (no glycan N1158)	NL
pCoV1B-01-PL	PL-S2P(12-1137)-del-4-Ferritin	Shortened ectodomain - no coiled coil (closest to flu HA pass off)	PL
pCoV1B-02-PL	PL-S2P(12-1137)-del-6-Ferritin	Shortened ectodomain - no coiled coil (closest to flu HA pass off)	PL
pCoV1B-03-PL	PL-S2P(12-1208)-del-Ferritin	Full ectodomain	PL
pCoV1B-04-PL	PL-S2P(12-1208)-GCN4-Ferritin	Full ectodomain with GCN4	PL
pCoV1B-05-PL	PL-S2P(12-1154)-del-Ferritin	Shortened ectodomain with ending with a couple turns of coiled coil	PL
pCoV-1B-06-PL (aka SpFN)	PL-S2P(12-1158)op1-del-Ferritin	Optimized HR ending (end on glycan N1158)	PL
pCoV1B-07-PL	PL-S2P(12-1158)op2-del-Ferritin	Optimized HR ending (Ile) (end on glycan N1158)	PL
pCoV1B-08-PL	PL-S2P(12-1158)op1x2-del-Ferritin	Optimized HR ending (N1158 glycan removed, but exists on the repeated HR)	PL
pCoV1B-09-PL	PL-S2P(12-1158)op2x2-del-Ferritin	Optimized HR ending (Ile) (N1158 glycan removed, but exists on the repeated HR)	PL
pCoV1B-10-PL	PL-S2P(12-1158)op1-fGCN4-del-Ferritin	Optimized HR ending with GCN4 fused in register (no glycan N1158)	PL

RBD-Ferritin			
Construct ID	Description	Comment	Leader
pCoV03	His8-3C-RBD(331-527)-Ferritin	N-terminal His8 with HRV-3C cleavage site, GSGGGG linker between RBD and Ferritin	PL
pCoV29	His8-3C-RBD-3-Ferritin	SGG linker	PL
pCoV30	His8-3C-RBD-3-del-Ferritin	SGG linker, $\Delta$ first 10 residues in ferritin, then DIEK changed to DIIK	PL
pCoV31	His8-3C-RBD-6-del-Ferritin	P527G, $\Delta$ first 8 residues in ferritin, then SKDIEK changed to DIIK	PL
pCoV1A-01	His8-3C-RBD-PPII-Ferritin	Extend distance between RBD and ferritin - using polyproline Helix	PL
pCoV1A-02	His8-3C-RBD-alpha1-Ferritin	Extend distance between RBD and ferritin - using alpha Helix from bottom of S protein	PL
pCoV1A-03	His8-3C-RBD-alpha2-Ferritin	Extend distance between RBD and ferritin- using alpha Helix from bottom of S protein	PL
pCoV1A-04	His8-3C-RBD-GCN4-del-Ferritin	Extend distance between RBD and ferritin + stabilize ferritin - using GCN4 trimerization motif	PL

pCoV1A-05	His8-3C-RBD-1141_1158op1-del-Ferritin	Extend distance between RBD and ferritin + stabilize ferritin - using semi-native trimerization motif	PL
pCoV1A-06	His8-3C-RBD-1141_1158op1x2-del-Ferritin	Extend distance between RBD and ferritin + stabilize ferritin - using semi-native trimerization motif	PL
pCoV49	His8-3C-RBD-F456N/K458T-Ferritin	RBD with indicated point mutations	PL
pCoV50	His8-3C-RBD-L455R/Y449K/F490R-Ferritin	RBD with indicated point mutations	PL
pCoV51	His8-3C-RBD-L455R-Ferritin	RBD with indicated point mutation	PL
pCoV52	His8-3C-RBD-I468R-Ferritin	RBD with indicated point mutation	PL
pCoV53	His8-3C-RBD-Y453R-Ferritin	RBD with indicated point mutation	PL
pCoV54	His8-3C-RBD-L452R-Ferritin	RBD with indicated point mutation	PL
pCoV55	His8-3C-RBD-L492R-Ferritin	RBD with indicated point mutation	PL
pCoV56	His8-3C-RBD-F490R-Ferritin	RBD with indicated point mutation	PL
pCoV57	His8-3C-RBD-F490A-Ferritin	RBD with indicated point mutation	PL
pCoV58	His8-3C-RBD-L518N/L519K/H520S-Ferritin	RBD with indicated point mutations	PL
pCoV59	His8-3C-RBD-L518R-Ferritin	RBD with indicated point mutation	PL
pCoV60	His8-3C-RBD-V367T/L335N-Ferritin	RBD with indicated point mutations	PL
pCoV61	His8-3C-RBD-T385N/L387T-Ferritin	RBD with indicated point mutations	PL
pCoV62	His8-3C-RBD-V382R-Ferritin	RBD with indicated point mutation	PL
pCoV63	His8-3C-RBD-F377R-Ferritin	RBD with indicated point mutation	PL
pCoV127	His8-3C-RBD-F490A/L518N/L519K/H520S-Ferritin	RBD with indicated point mutations	PL
pCoV128	His8-3C-RBD-F490A/L518R-Ferritin	RBD with indicated point mutations	PL
pCoV129	His8-3C-RBD-L455R/Y449K/F490R/L518N/L519K/H520S-Ferritin	RBD with indicated point mutations	PL
pCoV130	His8-3C-RBD-L455R/Y449K/F490R/L518R-Ferritin	RBD with indicated point mutations	PL
pCoV131 (aka RFN)	His8-3C-RBD-Y453R/L518N/L519K/H520S-Ferritin	RBD with indicated point mutations	PL
pCoV132	His8-3C-RBD-Y453R/L518R-Ferritin	RBD with indicated point mutations	PL

RBD-NTD-Ferritin			
Construct ID	Description		
pCoV122	His8-3C-RBD(331-527)-GSGGSG-NTD(12-303)-Ferritin	N-terminal His8 with HRV-3C cleavage site, GSGGSG linker between RBD and NTD, GSGGGG linker between NTD and Ferritin	PL
pCoV123	His8-3C-RBD-F490R-NTD-Ferritin	RBD with indicated point mutation	PL
pCoV124	His8-3C-RBD-F490A-NTD-Ferritin	RBD with indicated point mutation	PL
pCoV125	His8-3C-RBD-L518N/L519K/H520S-NTD-Ferritin	RBD with indicated point mutations	PL
pCoV126	His8-3C-RBD-L518R-NTD-Ferritin	RBD with indicated point mutation	PL
pCoV146	His8-3C-RBD-Y453R-L518N/L519K/H520S-NTD-Ferritin	RBD with indicated point mutations	PL
pCoV147	His8-3C-RBD-F490A-L518N/L519K/H520S-NTD-Ferritin	RBD with indicated point mutations	PL

S1-Ferritin			
Construct ID	Description		
pCoV68	S1(12-678)-Ferritin	GSGGSG linker between S1 and Ferritin	PL
pCoV107	S1(12-655)-Ferritin	24 residues removed from the C-terminus	PL
pCoV108	S1(12-655)-L611N/Q613T-Ferritin	24 residues removed from the C-terminus, S1 with indicated point mutations	PL
pCoV109	S1(12-696)-Ferritin	Extended the sequence to include a portion of S2	PL
pCoV110	S1(12-676)-G-S2(689-696)-Ferritin	Extended the sequence to include a portion of S2 with the indicated leader between the two regions	PL
pCoV111	S1(12-676)-GG-S2(689-696)-Ferritin	Extended the sequence to include a portion of S2 with the indicated leader between the two regions	PL
pCoV112	S1(12-676)-PG-S2(689-696)-Ferritin	Extended the sequence to include a portion of S2 with the indicated leader between the two regions	PL
pCoV113	S1-Y312N/Q313Y/T314T-Ferritin	S1 with indicated point mutations	PL
pCoV114	S1-I651N/A653S-Ferritin	S1 with indicated point mutations	PL
pCoV115	S1-S316C/V595C-Ferritin	S1 with indicated point mutations	PL
pCoV116	S1-V320C/S591C-Ferritin	S1 with indicated point mutations	PL
pCoV117	S1-L560Q/F562H-Ferritin	S1 with indicated point mutations	PL
pCoV118	S1-F562N/Q564T-Ferritin	S1 with indicated point mutations	PL
pCoV119	S1-F490R-Ferritin	S1 with indicated point mutation	PL
pCoV120	S1-F490A-Ferritin	S1 with indicated point mutation	PL
pCoV02	S1(16-678)-Ferritin	4 residues removed from N-terminus	PL
pCoV67	His8-3C-S1-Ferritin	His8 and HRV-3C cleavage site added to N-terminus	PL

1043  
1044

1045 **Table S2. Negative-stain Electron Microscopy Data Collection and Refinement**  
1046

Protein	SpFN_1B-06-PL	RFN_131	pCoV146	pCoV111	pCoV1B-05
Immunogen Fused	Spike (S2P)	RBD	RBD-NTD	S1	Spike (S2P)
EMPIAR Code	XXXXXX	XXXXXX	XXXXXX	XXXXXX	XXXXXX
EMDB Code	XXXX	XXXX	XXXX	XXXX	XXXX
<b>Data Collection</b>					
Microscope	Tecnai T20	Tecnai T20	Tecnai T20	Tecnai T20	Talos L120C
Voltage (kV)	200 kV	200 kV	200 kV	200 kV	120 kV
Camera	Eagle 4K	Eagle 4K	Eagle 4K	Eagle 4K	Ceta
Software	SerialEM	SerialEM	SerialEM	SerialEM	EPU
Pixel Size (Å/pix)	2.195	2.195	2.195	2.195	2.542
Underfocus range	0.7-1.3	0.8-1.3	0.6-1.5	0.8-1.6	0.5-0.9
<b>Image Processing</b>					
Software	RELION 3.0.8	RELION 3.0.8	RELION 3.0.8	RELION 3.0.8	RELION 3.1.1
# Particle Images	11502	3383	832	2121	2143
Pixel Size (Å/pixel)	4.39	4.39	4.39	4.39	5.084
Box Size (pixels)	160	160	160	160	200
Symmetry (3D)	O	O	O	O	--
Initial Lowpass (Å) (RELION)	100	80	100	100	--
High-res Limit (Å) (cisTEM)	--	--	--	--	--
Resolution (Å)	25	21	30	30	--

1047

1048 **Table S3. Mouse immunogenicity study immunogens, adjuvants, and mouse type**

pCOV no.	Immunogen design category, Study design	C57BL/6 ALFQ	Balb/c ALFQ	C57BL/6 Alhydrogel	Balb/c Alhydrogel
1B-05	S-Trimer-Ferritin	X	X		
1B-06-PL	S-Trimer-Ferritin	X	X	X	X
<b>RBD-Ferritin constructs</b>					
pCOV no.	Immunogen design category, Study design	C57BL/6 ALFQ	Balb/c ALFQ	C57BL/6 Alhydrogel	Balb/c Alhydrogel
50	RBD-Ferritin		X		
58	RBD-Ferritin	X	X	X	X
59	RBD-Ferritin		X		
127	RBD(57+58)-Ferritin	X	X	X	X
129	RBD(50+58)-Ferritin	X	X	X	X
130	RBD(50+59)-Ferritin		X		
131	RBD(53+58)-Ferritin	X	X	X	X
<b>S1-Ferritin constructs</b>					
pCOV no.		C57BL/6 ALFQ	Balb/c ALFQ	C57BL/6 Alhydrogel	Balb/c Alhydrogel
111	S1-Ferritin	X	X		
<b>RBD-NTD-Ferritin constructs</b>					
pCOV no.	Immunogen design category, Study design	C57BL/6 ALFQ	Balb/c ALFQ	C57BL/6 Alhydrogel	Balb/c Alhydrogel
122	RBD-NTD-Ferritin	X	X		
125	RBD(58)-NTD-Ferritin		X		X
146	RBD(53+58)-NTD-Ferritin	X	X	X	X
147	RBD(57+58)-NTD-Ferritin	X			

1049

1050 **Table S4. Animal immunogenicity SARS-CoV-2 pseudovirus neutralization ID50 and ID80**  
 1051 Numbers shown are the ID50/ID80 geometric mean titers for a group, with study week 2, 5, and 8 shown in vertical  
 1052 order.  
 1053

pCOV no.	Immunogen design category, Study design	C57BL/6 ALFQ	Balb/c ALFQ	C57BL/6 Alhydrogel	Balb/c Alhydrogel
1B-05	S-Trimer-Ferritin (x 2 groups)	702/189 8,709/2,346 13,076/5,647	115/<80 3,934/716 5,546/1,447		
1B-06-PL	S-Trimer-Ferritin	14,976/5,396 41,237/16,8184 7,323/16,52	1,152/355 16,816/6,662 25,062/6,540		
<b>RBD-Ferritin constructs</b>					
pCOV no.	Immunogen design category, Study design	C57BL/6 ALFQ	Balb/c ALFQ	C57BL/6 Alhydrogel	Balb/c Alhydrogel
50	RBD-Ferritin		X		
58	RBD-Ferritin	577/238 11,224/2,793 31,562/10,09	353/123 13,466/3,802 25,340/7,692	293/211 1,734/688 5,097/1261	232/<80 4,836/1,086 9,439/2,569
59	RBD-Ferritin		X		
127	RBD(57+58)-Ferritin	X	X	X	X
129	RBD(50+58)-Ferritin	X	X	X	X
130	RBD(50+59)-Ferritin		X		
131	RBD(53+58)-Ferritin	358/107 15,950/5,667 38,110/12,824	270/95 13,090/3,539 32,969/10,079	682/163 1,181/403 2,845/529	119/<40 182/103 240/99
<b>S1-Ferritin constructs</b>					
pCOV no.		C57BL/6 ALFQ	Balb/c ALFQ	C57BL/6 Alhydrogel	Balb/c Alhydrogel
111	S1-Ferritin	1,770/350 14,893/3,636 19,157/5,564	450/172 18,112/3,846 17,108/3,886		
<b>RBD-NTD-Ferritin constructs</b>					
pCOV no.	Immunogen design category, Study design	C57BL/6 ALFQ	Balb/c ALFQ	C57BL/6 Alhydrogel	Balb/c Alhydrogel
122	RBD-NTD-Ferritin	X	X		
125	RBD(58)-NTD-Ferritin		X		X
146	RBD(53+58)-NTD-Ferritin	230/91 16,678/4,356 20,107/6,126	240/89 31,252/7,190 24,854/6,744	<80/<80 667/460 940/289	662/<80 2,087/537 2,417/701
147	RBD(57+58)-NTD-Ferritin	X			

1054

## 1055 **Materials and Methods**

### 1056 ***Immunogen Modeling and Design***

1057 Following release of the SARS-CoV-2 sequence on Jan 10<sup>th</sup> 2020, initial RBD-Ferritin and S1-Ferritin  
1058 immunogens were designed (Table S1). Subsequent iterative immunogen design and optimization utilized  
1059 atomic models of the SARS-CoV-2 RBD molecule (Joyce et al., 2020), or the SARS-2 S trimer structure  
1060 PDB ID: 6VXX, and PDB ID: 3BVE for the *Helicobacter pylori* Ferritin, and PDB ID: 4LQH for the  
1061 bullfrog linker sequence. Pymol (Schrödinger) was used to generate the ferritin 24- subunit particle, and a  
1062 map created in UCSF Chimera (Pettersen et al., 2004) was supplied to cisTEM (Grant et al., 2018)  
1063 “align\_symmetry” to align the ferritin particle to an octahedral symmetry convention. This was supplied to  
1064 “phenix.map\_symmetry” to generate a symmetry file and PDB file, for octahedral (for monomer-fusions)  
1065 and D4 (for trimer-fusions) symmetry. S-domain ferritin nanoparticle fusions were modelled using Pymol  
1066 and Coot (Emsley et al., 2010) and expanded using “phenix.apply\_ncs” (Liebschner et al., 2019). Visual  
1067 analysis and figure generation was conducted using ChimeraX and PyMOL.

1068 RBD-Ferritin designs were generated by assessment of the hydrophobic surface of the SARS-CoV-  
1069 2 RBD surface and determining surface accessible mutations that reduced the hydrophobic surface. S1-  
1070 Ferritin designs were creating using the PDB ID: 6VXX and including a short region of the S2 domain,  
1071 which interacts with S1. Spike-Ferritin designs were created by modeling the coiled-coil region between S  
1072 residues 1140 and 1158 and increasing the coil-coil interaction either by mutagenesis, or by increasing the  
1073 length of the interaction region. RBD-NTD-Ferritin designs utilized RBD constructs with improved  
1074 properties in the context of RBD-Ferritin, which were fused to the N-terminus of NTD (12 - 303)-Ferritin  
1075 by a short 6 amino-acid linker.

### 1076 ***DNA plasmid construction and preparation***

1078 SARS-CoV-2 S-domain ferritin constructs were derived from the Wuhan-Hu-1 strain genome sequence  
1079 (GenBank MN9089473), to include the following domains: RBD subunit (residues 331 - 527), NTD subunit  
1080 (residues 12 - 303), RBD subunit linked to NTD subunit (residues 331 - 527 linked to residues 12 - 303  
1081 with a short GSG linker), S1 domain (residues 12 - 696) and S ectodomain (residues 12 – 1158). Constructs  
1082 were modified to incorporate a N-terminal hexa-histadine tag (his) for purification of the RBD-Ferritin and  
1083 RBD-NTD-Ferritin constructs.

1084 An S-2P construct was used as a template to generate the set of Spike ferritin nanoparticles.  
1085 Subsequent designs involving small deletions, additions and point mutations were generated using a  
1086 modified QuikChange site-directed mutagenesis protocol (Agilent). RBD-ferritin and S1-ferritin constructs  
1087 were synthesized by GenScript. For some of the RBD-ferritin constructs, gene segments (gBlocks) were  
1088 synthesized by Integrated DNA Technologies to encode various linker regions between RBD and ferritin.  
1089 Gene segments were stitched together with RBD- and ferritin-encoding PCR products using overlap  
1090 extension PCR and were re-subcloned into the CMVR vector. The His-tagged SARS-CoV-2 RBD molecule  
1091 was generated by amplifying the RBD domain from the RBD-Ferritin plasmid while encoding the 3'  
1092 purification tag and subcloned into the CMVR vector. The NTD protein subunit was generated in a similar  
1093 manner, by amplifying the NTD domain from the S1-Ferritin construct. For expression of S, RBD, and  
1094 NTD proteins, the S protein domains were cloned into the CMVR expression plasmid using the  
1095 NotI/BamHI restriction sites. Constructs including the N-terminal region of the S protein included the native  
1096 leader sequence; for constructs not including this region we utilized a prolactin leader (PL) sequence  
1097 (Boyington et al., 2016).

1098 Plasmid DNA generated by subcloning (restriction digest and ligation) was amplified in and  
1099 isolated from E. coli Top10 cells. The constructs resulting from site-directed mutagenesis were either  
1100 amplified in and isolated from E. coli Stbl3 or Top10 cells. Large-scale DNA isolation was performed using  
1101 either endo free Maxiprep, Megaprep or Gigaprep kits (Qiagen).

### 1102 ***Immunogen expression and purification***

1104 All expression vectors were transiently transfected into Expi293F cells (Thermo Fisher Scientific)  
1105 using ExpiFectamine 293 transfection reagent (Thermo Fisher Scientific). Cells were grown in



1106 polycarbonate baffled shaker flasks at 34°C or 37°C and 8% CO<sub>2</sub> at 120 rpm. Cells were harvested 5-6 days  
1107 post-transfection via centrifugation at 3,500 x g for 30 minutes. Culture supernatants were filtered with a  
1108 0.22-µm filter and stored at 4 °C prior to purification.

1109 His-tagged proteins were purified using Ni-NTA affinity chromatography, while untagged proteins  
1110 were purified with GNA lectin affinity chromatography. Briefly, 25 mL GNA-lectin resin (VectorLabs)  
1111 was used to purify untagged protein from 1L of expression supernatant. GNA resin was equilibrated with  
1112 10 column volumes (CV) of phosphate buffered saline (PBS) (pH 7.4) followed by supernatant loading  
1113 twice at 4 °C. Unbound protein was removed by washing with 20 CV of PBS buffer. Bound protein was  
1114 eluted with 250mM methyl- $\alpha$  -D mannopyranoside in PBS buffer (pH 7.4). His-tagged proteins were  
1115 purified using Ni-NTA affinity chromatography. 1 mL Ni-NTA resin (Thermo Scientific) was used to  
1116 purify protein from 1L of expression supernatant. Ni-NTA resin was equilibrated with 5 CV of phosphate  
1117 buffered saline (PBS) (pH 7.4) followed by supernatant loading 2x at 4 °C. Unbound protein was removed  
1118 by washing with 200 CV of PBS, followed by 50 CV 10mM imidazole in PBS. Bound protein was eluted  
1119 with 220mM imidazole in PBS. For all proteins, purification purity was assessed by SDS-PAGE. RBD-  
1120 Ferritin nanoparticle constructs had a propensity to form soluble or insoluble aggregates which affected the  
1121 ability to concentrate the samples. Addition of 1mM EDTA and 5% glycerol to the NiNTA purified  
1122 material, prior to SEC or other concentration steps, mitigated the aggregation issue, and increased the  
1123 nanoparticle formation as judged by SEC, and confirmed by neg-EM. All proteins were further purified by  
1124 size-exclusion chromatography using a 16/60 Superdex-200 purification column. Purification purity for all  
1125 the proteins was assessed by SDS-PAGE. Removal of the His-tags for SARS2-CoV-2 S-2P and RBD for  
1126 use in ELISA were carried out using HRV-3C protease. Endotoxin levels for ferritin nanoparticle  
1127 immunogens were assessed (Endosafe® nexgen-PTS, Charles River Laboratories) and 5 % v/v glycerol  
1128 was added prior to filter-sterilization with a 0.22-µm filter, flash-freezing in liquid nitrogen, and storage at  
1129 -80 °C. Ferritin nanoparticle formation was assessed by dynamic light scattering (DLS) by determining the  
1130 hydrodynamic diameter at 25 °C using a Malvern Zetasizer Nano S (Malvern, Worcestershire, UK)  
1131 equipped with a 633-nm laser.

1132 For the antibodies, plasmids encoding heavy and light chains of antibodies (CR3022, and SR1-  
1133 SR5) were co-transfected into Expi293F cells (ThermoFisher) according to the manufacturer's instructions  
1134 for expression of antibodies. After 5 days, antibodies were purified from cleared culture supernatants with  
1135 Protein A agarose (ThermoFisher) using standard procedures, buffer was exchanged to PBS by dialysis,  
1136 and antibody concentration was quantified using calculated extinction coefficient and A280 measurements.

### 1137 1138 ***Negative-stain Electron Microscopy***

1139 Purified proteins were deposited at 0.02-0.08 mg/ml on carbon-coated copper grids and stained with 0.75%  
1140 uranyl formate. Grids were imaged using a FEI T20 operating at 200 kV with an Eagle 4K CCD using  
1141 SerialEM or using a Thermo Scientific Talos L120C operating at 120 kV with Thermo Scientific Ceta using  
1142 EPU. All image processing steps were done using RELION 3.0.8, RELION 3.1.1, and/or cisTEM-1.0.0-  
1143 beta. Particles were picked either manually or using templates generated from manually picked 2D class  
1144 averages. CTF estimation was done with CTFFIND 4.1.13 and used for 2D classification. 3D  
1145 reconstructions were generated using an initial reference generated from a corresponding synthetic atomic  
1146 model with a low pass filter of 80-100 angstroms to remove distinguishable features or from a similar  
1147 construct also low pass filtered to 80-100 angstroms. For all 3D reconstructions, O symmetry was enforced,  
1148 and no explicit mask was used. Visual analysis and figure generation was conducted using Chimera and  
1149 ChimeraX.

### 1150 1151 ***Dynamic Light Scattering***

1152 Spike-domain ferritin nanoparticle hydrodynamic diameter was determined at 25°C using a Malvern  
1153 Zetasizer Nano S (Malvern, Worcestershire, UK) equipped with a 633-nm laser. Samples were assessed  
1154 accounting for the viscosity of their respective buffers.

### 1155 1156 ***Octet Biolayer Interferometry binding and ACE2 inhibition assays***

1157 All biosensors were hydrated in PBS prior to use. All assay steps were performed at 30°C with agitation  
1158 set at 1,000 rpm in the Octet RED96 instrument (FortéBio). Biosensors were equilibrated in assay buffer  
1159 (PBS) for 15 seconds before loading of IgG antibodies (30 µg/ml diluted in PBS). SARS-COV-2 antibodies  
1160 were immobilized onto AHC biosensors (FortéBio) for 100 seconds, followed by a brief baseline in assay  
1161 buffer for 15 s. Immobilized antibodies were then dipped in various antigens for 100-200 s followed by  
1162 dissociation for 20-100 s.

1163 Mouse sera binding to the SARS-CoV-2 RBD, VoC RBDs, or SARS-CoV-1 RBD were carried out  
1164 as follows. HIS1K biosensors(FortéBio) were equilibrated in assay buffer for 15 s before loading of His-  
1165 tagged RBD (30 µg/ml diluted in PBS) for 120 seconds. After briefly dipping in assay buffer (15 seconds  
1166 in PBS), the biosensors were dipped in mouse sera (100-fold dilution) for 180 seconds followed by  
1167 dissociation for 60 seconds.

1168 SARS-CoV-2 and SARS-CoV-1 RBD hACE2 inhibition assays were carried out as follows. SARS-  
1169 CoV-2 or SARS-CoV-1 RBD (30 µg/ml diluted in PBS) was immobilized on HIS1K biosensors (FortéBio)  
1170 for 180 seconds followed by baseline equilibration for 30 s. Serum was allowed to occur for 180 s followed  
1171 by baseline equilibration (30 s). ACE2 protein (30 µg/ml) was the allowed to bind for 120 s. Percent  
1172 inhibition (PI) of RBD binding to ACE2 by serum was determined using the equation:  $PI = 100 - [(ACE2$   
1173  $binding\ in\ the\ presence\ of\ mouse\ serum)] / (mouse\ serum\ binding\ in\ the\ absence\ of\ competitor\ mAb) \times$   
1174  $100$ .

### 1175 1176 ***Mouse immunization***

1177 All research in this study involving animals was conducted in compliance with the Animal Welfare Act,  
1178 and other federal statutes and regulations relating to animals and experiments involving animals and  
1179 adhered to the principles stated in the Guide for the Care and Use of Laboratory Animals, NRC Publication,  
1180 1996 edition. The research protocol was approved by the Institutional Animal Care and Use Committee of  
1181 WRAIR. BALB/c and C57BL/6 mice were obtained from Jackson Laboratories (Bar Harbor, ME). Mice  
1182 were housed in the animal facility of WRAIR and cared for in accordance with local, state, federal, and  
1183 institutional policies in a National Institutes of Health American Association for Accreditation of  
1184 Laboratory Animal Care-accredited facility.

1185 C57BL/6 or BALB/c mice (n=10/group) were immunized intramuscularly with 10 µg of  
1186 immunogen (unless stated) adjuvanted with either ALFQ or Alhydrogel® in alternating caudal thigh  
1187 muscles three times, at 3-week intervals; blood was collected 2 weeks before the first immunization, the  
1188 day of the first immunization, and 2 weeks following each immunization, and at week 10 (Table S1). For  
1189 immunogen SpFN\_1B-06-PL, mice were immunized with reduced doses of protein adjuvanted with ALFQ  
1190 with immunization schedule, site of injections, and timing of bleeds as described. Mice were randomly  
1191 assigned to experimental groups and were not pre-screened or selected based on size or other gross physical  
1192 characteristics. Serum was stored at 4°C or -80°C until analysis. Antibody responses were analyzed by  
1193 Octet Biolayer Interferometry, enzyme-linked immunosorbent assay (ELISA), pseudovirus neutralization  
1194 assay, and live-virus neutralization assay.

### 1195 1196 ***Immunogen-Adjuvant preparation***

1197 Purified research grade nanoparticle immunogens were formulated in PBS with 5% glycerol at 1 mg/ml  
1198 and subsequently diluted with dPBS (Quality Biological) to provide 10 µg or lower amount per 50 µl dose  
1199 upon mixing with adjuvant. ALFQ (1.5X) liposomes, containing 600 µg/mL 3D-PHAD and 300 µg/mL  
1200 QS-21, were gently mixed by slow speed vortex prior to use. Antigen was added to the ALFQ, vortexed at  
1201 a slow speed for 1 minute, mixed on a roller for 15 minutes, and stored at 4°C for 1 h prior to immunization.  
1202 Spike-Ferritin nanoparticle immunogens were formulated with ALFQ to contain 20 µg 3D-PHAD and 10  
1203 µg QS21 per 50 µl dose. Alhydrogel® stock (10 mg/ml aluminum (GMP grade; Brenntag)) was diluted to  
1204 900 µg/mL (1.5X) with DPBS and gently mixed. Appropriate volume and concentration of antigen was  
1205 added to the diluted Alhydrogel® before being vortexed at low speed for 1 min, mixed on a roller for 15  
1206 minutes, and stored at 4°C for at least 1 h prior to immunization. Spike-Ferritin nanoparticle immunogens  
1207 were adsorbed to Alhydrogel® aluminum hydroxide at 30 µg aluminum per 50 µl dose.

1208

1209 ***Enzyme Linked Immunosorbent Assay (ELISA)***

1210 96-well Immulon “U” Bottom plates were coated with 1 µg/mL of RBD or S protein (S-2P) antigen in PBS,  
1211 pH 7.4. Plates were incubated at 4°C overnight and blocked with blocking buffer (Dulbecco’s PBS  
1212 containing 0.5% milk and 0.1% Tween 20, pH 7.4, at room temperature (RT) for 2 h. Individual serum  
1213 samples were serially diluted 2-fold in blocking buffer and added to triplicate wells and the plates were  
1214 incubated for 1 hour (h) at RT. Horseradish peroxidase (HRP)-conjugated sheep anti-mouse IgG, gamma  
1215 chain specific (The Binding Site) was added and incubated at RT for an hour, followed by the addition of  
1216 2,2'-Azinobis [3-ethylbenzothiazoline-6-sulfonic acid]-diammonium salt (ABTS) HRP substrate (KPL) for  
1217 1 h at RT. The reaction was stopped by the addition of 1% SDS per well and the absorbance (A) was  
1218 measured at 405 nm (A405) using an ELISA reader Spectramax (Molecular Devices, San Jose, CA) ) within  
1219 30 min of stopping the reaction.. Antibody positive (anti-RBD mouse mAb; BEI resources) and negative  
1220 controls were included on each plate. The results are expressed as end point titers, defined as the reciprocal  
1221 dilution that gives an absorbance value that equals twice the background value (antigen-coated wells that  
1222 did not contain the test sera, but had all other components added).

1223 Mouse isotype ELISA were performed using a similar approach as above, but with the following  
1224 differences. Only Spike protein (S-2P) was used to coat the wells. The plates were blocked with PBS  
1225 containing 0.2% bovine serum albumin (BSA), pH 7.4 for 30 minutes. The mouse serum samples were  
1226 serially diluted in duplicates either 3- or 4-fold in PBS containing 0.2% BSA and 0.05% Tween 20, pH7.4.  
1227 The secondary antibodies were HRP-conjugated AffiniPure Goat Anti-Mouse antibodies from Jackson  
1228 ImmunoResearch specific for either Fcγ subclass 1, Fcγ subclass 2a, or Fcγ subclass 2c. The secondary  
1229 antibodies were incubated for 30 minutes. TMB (3,3',5,5'-Tetramethylbenzidine) substrate (Thermo) was  
1230 added and the plates were incubated at RT for 5-10 minutes to allow color development. Stop solution  
1231 (Thermo) was added and the A405 was measured using a VersaMax microplate reader (Molecular Devices).  
1232 A titration curve of serum concentration versus A450 was created. The titration curves were interpolated to  
1233 determine the dilution factor where A450=1.0 for each mouse sera sample and IgG subclass, and the  
1234 resulting values were used to calculate the IgG1/IgG2a ratio (for BALB/c mice) or IgG1/IgG2c ratio (for  
1235 C57BL/6 mice). In the animal groups immunized with SpFN\_1B-06-PL with the adjuvant Alhydrogel®,  
1236 many of the mouse IgG usage ratio could not be calculated due to insufficient signal for either IgG2a or  
1237 IgG2c in the mouse sera.

1238

1239 ***SARS-CoV-2 and SARS-CoV-1 pseudovirus neutralization assay***

1240 The S expression plasmid sequences for SARS-CoV-2 (Wuhan1, B.1.1.7, and B.1.351) and SARS-CoV  
1241 were codon optimized and modified to remove an 18 amino acid endoplasmic reticulum retention signal in  
1242 the cytoplasmic tail in the case of SARS-CoV-2, and a 28 amino acid deletion in the cytoplasmic tail in the  
1243 case of SARS-CoV. This allowed increased S incorporation into pseudovirions (PSV) and thereby enhance  
1244 infectivity. Virions pseudotyped with the vesicular stomatitis virus (VSV) G protein were used as a non-  
1245 specific control. SARS-CoV-2 pseudovirions (PSV) were produced by co-transfection of HEK293T/17  
1246 cells with a SARS-CoV-2 S plasmid (pcDNA3.4) and an HIV-1 NL4-3 luciferase reporter plasmid (The  
1247 reagent was obtained through the NIH HIV Reagent Program, Division of AIDS, NIAID, NIH: Human  
1248 Immunodeficiency Virus 1 (HIV-1) NL4-3 ΔEnv Vpr Luciferase Reporter Vector (pNL4-3.Luc.R-E-),  
1249 ARP-3418, contributed by Dr. Nathaniel Landau and Aaron Diamond). The SARS-CoV-2 S expression  
1250 plasmid sequence was derived from the Wuhan seafood market pneumonia virus isolate Wuhan-Hu-1,  
1251 complete genome (GenBank accession MN908947), and the SARS-CoV-1 expression plasmid was derived  
1252 from the Urbani S sequence.

1253           Infectivity and neutralization titers were determined using ACE2-expressing HEK293 target cells  
1254 (Integral Molecular) in a semi-automated assay format using robotic liquid handling (Biomek NXp  
1255 Beckman Coulter). Test sera were diluted 1:40 in growth medium and serially diluted, then 25  $\mu$ L/well was  
1256 added to a white 96-well plate. An equal volume of diluted SARS-CoV-2 PSV was added to each well and  
1257 plates were incubated for 1 hour at 37°C. Target cells were added to each well (40,000 cells/ well) and  
1258 plates were incubated for an additional 48 hours. RLUs were measured with the EnVision Multimode Plate  
1259 Reader (Perkin Elmer, Waltham, MA) using the Bright-Glo Luciferase Assay System (Promega  
1260 Corporation, Madison, WI). Neutralization dose-response curves were fitted by nonlinear regression with  
1261 a five-parameter curve fit using the LabKey Server® (Piehler et al., 2011), and the final titers are reported  
1262 as the reciprocal of the dilution of serum necessary to achieve 50% neutralization (ID50, 50% inhibitory  
1263 dilution) and 80% neutralization (ID80, 80% inhibitory dilution). Assay equivalency for SARS-CoV-2 was  
1264 established by participation in the SARS-CoV-2 Neutralizing Assay Concordance Survey (SNACS) run by  
1265 the Virology Quality Assurance Program and External Quality Assurance Program Oversight Laboratory  
1266 (EQAPOL) at the Duke Human Vaccine Institute, sponsored through programs supported by the National  
1267 Institute of Allergy and Infectious Diseases, Division of AIDS.  
1268

#### 1269 ***SARS-CoV-2 authentic virus neutralization assay***

1270 The neutralization assay has been described in detail previously (Case et al., 2020). Briefly, SARS-CoV-2  
1271 strain 2019-nCoV/USA\_WA1/2020 was obtained from the Centers for Disease Control and Prevention.  
1272 Virus was passaged once in Vero CCL81 cells (ATCC) and titrated by focus-forming assay on Vero E6  
1273 cells. Mouse sera were serially diluted and incubated with 100 focus-forming units of SARS-CoV-2 for 1  
1274 h at 37°C. Serum-virus mixtures were then added to Vero E6 cells in 96-well plates and incubated for 1 h  
1275 at 37°C. Cells were overlaid with 1% (w/v) methylcellulose in MEM. After 30 h, cells were fixed with  
1276 4% PFA in PBS for 20 minutes at room temperature then washed and stained overnight at 4°C with 1  $\mu$ g/ml  
1277 of CR3022 (ter Meulen et al., 2006; Tian et al., 2020) in PBS supplemented with 0.1% saponin and 0.1%  
1278 bovine serum albumin. Cells were subsequently stained with HRP-conjugated goat anti-human IgG for 2 h  
1279 at room temperature. SARS-CoV-2-infected cell foci were visualized with TrueBlue peroxidase substrate  
1280 (KPL) and quantified using ImmunoSpot® microanalyzer (Cellular Technologies, Shaker Heights, OH).  
1281 Neutralization curves were generated using Prism software (GraphPad Prism 8.0).  
1282  
1283

#### 1284 ***Protection experiments in K18-hACE2 transgenic mice***


1285 All research in this study involving animals was conducted in compliance with the Animal Welfare Act,  
1286 and other federal statutes and regulations relating to animals and experiments involving animals and  
1287 adhered to the principles stated in the Guide for the Care and Use of Laboratory Animals, NRC Publication,  
1288 1996 edition. The research protocol was approved by the Institutional Animal Care and Use Committee of  
1289 the Trudeau Institute. K18-hACE2 transgenic mice were obtained from Jackson Laboratories (Bar Harbor,  
1290 ME). Mice were housed in the animal facility of the Trudeau Institute and cared for in accordance with  
1291 local, state, federal, and institutional policies in a National Institutes of Health American Association for  
1292 Accreditation of Laboratory Animal Care-accredited facility.  
1293


1294           To determine an appropriate challenge viral stock amount and establish the K18-hACE2 SARS-  
1295 CoV-2 mouse challenge model, five viral doses were used to inoculate the K18-hACE2 mice. Each study  
1296 group was composed of 10 hACE2 K18 Tg mice (5 males and 5 females). Mice were infected on study day  
1297 0 doses ranging from  $5 \times 10^2$  to  $1 \times 10^5$  PFU of SARS-CoV-2 USA-WA1/2020 administered via intranasal  
1298 instillation. All mice were monitored for clinical symptoms and body weight twice daily, every 12 hours,  
1299 from study day 0 to study day 14. Mice were euthanized if they displayed any signs of pain or distress as  
1300 indicated by the failure to move after stimulated or inappetence, or if mice have greater than 25% weight  
1301 loss compared to their study day 0 body weight. Hematoxylin and eosin staining of lung sections following  
infection with  $1.25 \times 10^4$  PFU compared to control uninfected mouse lung sections are shown in Figure S6.

1302 For the passive immunization study, on day -1, K18-hACE2 mice were injected intravenously with  
1303 purified IgG from C57BL/6 vaccinated mice. On study day 0, all mice were inoculated with  $1.25 \times 10^4$  PFU  
1304 of SARS-CoV-2 USA-WA1/2020 via intranasal instillation. All mice were monitored for clinical  
1305 symptoms and body weight twice daily, every 12 hours, from study day 0 to study day 14. Mice were  
1306 euthanized if they displayed any signs of pain or distress as indicated by the failure to move after stimulated  
1307 or inappetence, or if mice have greater than 25% weight loss compared to their study day 0 body weight.

1308  
1309 ***Data Analysis***

1310 Data analyses used GraphPad (San Diego, CA) Prism software and statistical tests as described for  
1311 individual experiments.






**Figure 2. Biophysical characterization of SARS-CoV-2 S-based ferritin nanoparticle vaccine candidates**

SDS-PAGE of (A) Spike ferritin nanoparticles, (B) RBD ferritin nanoparticles, (C) S1 ferritin nanoparticle, and (D) RBD-NTD ferritin nanoparticles. Molecular weight standards are indicated in kDa.

(E) Size-exclusion chromatography on a Superdex S200 10/300 column of representative SARS-CoV-2 S-based ferritin nanoparticles.

(F) Negative-stain electron microscopy 2D class averages of purified nanoparticles. The black bars represent 50 nm.

See also Figure S2 and S3.



**Figure 3. Antigenic characterization of select SARS-CoV-2 S-based ferritin nanoparticle vaccine candidates**

Binding response of SARS-CoV-2 neutralizing antibodies to each of the lead candidates from the four design categories measured by biolayer interferometry with two-fold serial dilution of each antibody starting at 30 µg/ml.

(A) Spike ferritin nanoparticle SpFN (pCoV1B-06-PL).


(B) RBD ferritin RFN (pCoV131).

(C) RBD-NTD ferritin nanoparticle pCoV146.

(D) S1 ferritin nanoparticle pCoV111.

See also Figure S3.





**Figure 4. Negative-Stain Electron Microscopy 3D Reconstructions of SARS-CoV-2 S-based ferritin nanoparticles**

Modifications made to native sequence and linkers used for each construct are shown in schematic diagrams.


(A) Negative-stain 3D reconstructions with applied octahedral symmetry are shown with an asymmetric unit of non-ferritin density colored and the size of each particle indicated in nanometers. Spike trimer density, is colored in red, and a model of a SARS-CoV-2 trimer based on PDB 6VXX is shown docked into the negative-stain map and colored according to the sequence diagram.

(B) Two non-ferritin densities per asymmetric unit were observed for RFN and are highlighted in green. These densities putatively correspond to the receptor-binding domain (RBD) but lack low resolution distinguishing features due to the small, globular shape of these domains. The presence of two densities is likely due to flexibility in the linker and heterogeneity in the RBD pose.

(C) Two layers of densities were distinguishable for pCoV146, with the putative N-terminal domain (NTD) density of an asymmetric unit colored blue, proximal to the ferritin and two smaller, more flexible densities corresponding to RBD distal to the ferritin and colored green.

(D) An asymmetric unit of non-ferritin density for pCoV111 is colored in orange and a monomer of S1 in the closed trimer state from PDB 6VXX is shown docked into the density with domains colored as in the sequence diagram.

See also Figure S2 and Table S2




**Figure 5 SARS-CoV-2 S-domain nanoparticle vaccine candidates elicit robust binding and neutralizing antibody responses in C57BL/6 mice.**

Data relating to each category of immunogen are colored as follows: SpFN (blue), RFN (green), pCoV146 (black) and pCoV111 (orange). N= 10/group.

- (A) Biolayer interferometry binding of mouse sera to SARS-COV-2 RBD. Study week is indicated on the base of the graph. Mean value is indicated by a horizontal line. Statistical comparison at each timepoint was carried out using a Kruskal-Wallis test followed by a Dunn's post-test.
- (B) ELISA binding of mouse sera to SARS-COV-2 S-2P or RBD. Study week is indicated on the base of the graph. Geometric mean value is indicated by a horizontal line. Statistical comparison at each timepoint was carried out using a Kruskal-Wallis test followed by a Dunn's post-test.
- (C) SARS-CoV-2 pseudovirus neutralization ID50 and ID80 values. Geometric mean value is indicated by a horizontal line. Statistical comparisons at each given timepoint was carried out using a Kruskal-Wallis test followed by a Dunn's post-test.
- (D) Binding and pseudovirus neutralization of sera from mice immunized with 0.08 µg SpFN + ALFQ.
- (E) Authentic SARS-CoV-2 virus neutralization ID50 and ID80 are shown for mice immunized with 10 µg (blue) or 0.08 µg (light blue) SpFN + ALFQ. Geometric mean titer is indicated by a horizontal line. Comparisons between dose group at each time point were carried out using a Mann-Whitney unpaired two-tailed non-parametric test.

In panels A – C, all groups at a given study timepoint were compared to each other. Only groups with significant differences are indicated by a bar; all other groups did not show statistically significant differences. P values <0.0001 (\*\*\*\*), <0.001 (\*\*\*), <0.01 (\*\*), or <0.05 (\*).

See also Figure S4 and S5, and Table S3 and S4.



**Figure 6. SpFN- and RFN- protective immunity in K18-hACE2 transgenic mice.**

(A) IgG was purified from SPFN- or RFN-vaccinated mouse sera and passively transferred at specific IgG amounts ranging from 4 - 470 µg/mouse in a final volume of 200 µl. Control naïve mouse IgG was formulated at 2 mg/ml. (n=10/group, 5 female, 5 male).


(B) Mouse challenge study schematic. K18-hACE2 mice (n=10/group, 5 female, 5 male) received control IgG (black), PBS (gray), and purified IgG, one day prior to challenge with 1.25 x 10<sup>4</sup> PFU of SARS-CoV-2.

(C) SARS-CoV-2 pseudovirus neutralization ID<sub>50</sub> titers of mouse sera at study day 0.

(D) Percentage of initial weight of K18-hACE2 mice for the 8 study groups. Legend is shown in panel E.

(E) Survival curves of K18-hACE2 mice with groups indicated based on animal vaccination group and the pseudovirus ID<sub>50</sub> neutralization values. Statistical comparisons were carried out using Mantel-Cox test followed by Bonferroni correction.

See also Figure S6.



**Figure 7. SARS-CoV-2 S-domain nanoparticle vaccine candidates elicit robust antibody binding responses and neutralizing activity against SARS-CoV-2 VoC and SARS-CoV-1.**

(A) Biolayer Interferometry binding of study week 10 immunized C57BL/6 mouse serum to SARS-CoV-2 RBD, and SARS-CoV-2 RBD variants. Immunogens are indicated at the top left of each graph. Mean values are indicated by a horizontal line, n=10, Significance was assessed using a Kruskal-Wallis test followed by a Dunn's post-test.


(B) Pseudovirus neutralization (ID<sub>50</sub> values) of study week 10 immunized C57BL/6 and BALB/c mouse serum to SARS-CoV-2 Wuhan-1, B.1.1.7, and B.1.351 pseudotyped viruses. Immunogens are indicated at the base of each graph. Geometric mean values are indicated by a horizontal line, n=5, statistical significance for each immunogen was assessed using a Kruskal-Wallis test followed by a Dunn's post-test.

(C) Biolayer Interferometry binding of study week 10 immunized C57BL/6 and BALB/c mouse serum to SARS-CoV-1 RBD. Immunogens are indicated at the base of each graph. Mean values are indicated by a horizontal line, n=10, statistical significance was assessed using a Kruskal-Wallis test followed by a Dunn's post-test.

(D) Pseudovirus neutralization (ID<sub>50</sub> values) of study week 10 immunized C57BL/6 and BALB/c mouse serum to SARS-CoV-1 Urbani strain pseudotyped viruses. Data related to SpFN and RFN are colored blue and green respectively. Statistical comparisons between SpFN and RFN responses at each time point were carried out using a Mann-Whitney unpaired two-tailed non-parametric test.


Immunogens are indicated at the base of each graph. Geometric mean values are indicated by a horizontal line, n=10, P values <0.0001 (\*\*\*\*), <0.01 (\*\*) or <0.05 (\*).

See also Figure S4 and S5.



**Figure S1. Structure-based design of SARS-CoV-2 S-domain ferritin nanoparticle immunogens and design pipeline. Related to Figure 1.**

Four ferritin nanoparticle immunogen designs were developed focused on (1) Spike ferritin nanoparticles (blue), (2) RBD ferritin nanoparticles (green), (3) RBD-NTD ferritin nanoparticles (black), and (4) S1 ferritin nanoparticles (orange). The design iterations and concepts are indicated, along with select mutations and design name. Lead vaccine candidates from each category are highlighted.



**Figure S2. Negative-stain electron microscopy 2D micrographs of SARS-CoV-2 ferritin nanoparticle vaccine candidates, related to Figure 2 and 4.**


Negative-stain electron microscopy 2D micrographs. The white scale bars represent 100 nm.

(A) Spike ferritin nanoparticles pCoV1B-05 and pCoV1B-08.

(B) RBD ferritin nanoparticles pCoV03, pCoV50, pCoV58, pCoV59, pCoV127, pCoV129, pCoV130, pCoV131


(C) RBD-NTD ferritin nanoparticles pCoV122, pCoV125, pCoV147

(D) S1 ferritin nanoparticle pCoV110 and pCoV112.




**Figure S3. Biophysical and antigenic characterization of S-domain ferritin nanoparticle immunogens. Related to Figure 2 and 3.**

- (A) Size-exclusion chromatography on a Superdex S200 10/300 column of representative SARS-CoV-2 S-based ferritin nanoparticles from the four design categories.  
 (B) Expression levels (mg/L supernatant) of representative SARS-CoV-2 Spike-based ferritin nanoparticles.  
 (C) Dynamic light scattering analysis of representative SARS-CoV-2 Spike-based ferritin nanoparticles.  
 (D) Spike ferritin nanoparticles (E) RBD ferritin, (F) RBD-NTD ferritin and (G) S1 ferritin nanoparticles were assessed for binding to a set of neutralizing antibodies (concentration = 30  $\mu$ g/ml) by biolayer interferometry.







**Figure S5 SARS-CoV-2 SpFN vaccine candidate elicits robust binding and neutralizing antibody responses at reduced doses in mice. Related to Figure 5 and 7.**


(A) Biolayer interferometry analysis of C57BL/6 and (B) BALB/c mouse sera binding response to SARS-CoV-2 RBD following immunization with reducing doses of SpFN.

(C, E) ELISA analysis of C57BL/6 and (D, F) BALB/c mouse sera binding response to SARS-CoV-2 RBD or S-2P following immunization with reducing doses of SpFN.

(G) SARS-CoV-2 pseudovirus ID80 neutralization titers of mice immunized with 0.08 µg SpFN + ALFQ.

(H) Authentic SARS-CoV-2 virus ID80 neutralization titers of mice immunized with 10 µg (blue) or 0.08 µg (light blue) SpFN + ALFQ. Geometric mean titers for each group and time point are indicated by a horizontal line, n = 10. Neutralization titers for the two dose groups at each study time point were compared for statistically significant differences using a Mann-Whitney unpaired two-tailed non-parametric test. The two BALB/c time points that showed differences are indicated by bars. P values < 0.001 (\*\*\*), < 0.01 (\*\*).

(I) Mouse sera from study week 10 was analyzed for hACE2 blocking capacity to SARS-CoV-2 RBD (left) or SARS-CoV-1 RBD using a biolayer interferometry assay format.



**Figure S6 Histopathological analysis of SARS-CoV-2 infection in K18-ACE2 mice. Related to Figure 7**

(A, B) Hematoxylin and eosin staining of lung sections from K18-hACE2 mice following intranasal infection with  $1.25 \times 10^4$  PFU SARS-CoV-2. Images show two magnifications. Images are representative of  $n = 10$  per group.